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ABSTRACT 
 
 While cystic fibrosis (CF) is commonly thought of as a lung disease, since it’s first 
description 70 years ago we have come to understand that loss of CFTR (cystic fibrosis 
transmembrane conductance regulator) function affects numerous tissues and systems throughout 
the body.  Concerning the heart, right ventricular dysfunction secondary to pulmonary 
abnormalities has long been recognized.  However, the issue as to whether loss of CFTR 
function causes primary disturbances in the heart has remained an unsolved and often debated 
question.  Thus, the goal of the research presented herein was to answer two fundamental 
questions, 1) “Does CFTR play a physiological role in heart function?,” and 2) “What direct 
impact does loss of CFTR activity have on heart function?”  These are particularly timely 
questions now as CF patients are living longer and the development of CFTR modulators is 
being pursued with increased vigor.  Thus, an understanding if CF patients will be at increased 
risk for heart disease and whether new therapies may affect heart function are of direct relevance 
to the care of these individuals. 
 To begin to answer the questions presented we have examined how modulation of CFTR 
affects neonatal ventricular cardiomyocyte contraction rate.  We found that CFTR is involved in 
the regulation of both baseline and β-adrenergic stimulated contraction rate.  Additionally, loss 
of CFTR activity, whether acutely or chronically, leads to modulation of intracellular signaling 
molecules and other Cl- channels, which in some cases can completely compensate for this loss, 
while in other cases cannot.  Finally, in vivo examination of heart function in CFTR KO mice has 
elucidated disturbances in heart structure and function, which may translate into problems 
experienced by CF patients.  In sum, this work presents a significant expansion of our 
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understanding regarding the role of CFTR in heart function and highlights the need to further 
pursue a more in-depth analysis of the health of the heart in CF patients. 
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CHAPTER 1: 
PROPERTIES OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE 
REGULATOR AND ITS POTENTIAL RELEVANCE TO CARDIAC CONTRACTION 
RATE 
 
Cardiovascular disease is the number one killer in the United States.  Statistics taken in 
2004 by the American Heart Association show that over 74 million people are affected by 
cardiovascular diseases, with an economic impact over 430 billion dollars.  Diseases specifically 
affecting the heart, namely heart disease, stroke, and sudden cardiac death, account for a 
significant proportion of that impact (www.americanheart.org).  With a risk of sudden cardiac 
death six to nine times that of the general population, at least 50% of deaths in patients with heart 
failure are due to ventricular arrhythmias (1, 2).  Therefore, understanding the physiological and 
pathophysiological processes in the heart remains an important area of investigation. 
 
CARDIOMYOCYTE CONTRACTION RATE AND THE ROLE OF ION CHANNELS IN 
RATE MODULATION 
Cardiac muscle, like skeletal muscle, is a striated muscle and thus the two muscle types 
share many characteristics.  However, the electrophysiology of the two muscle types differs 
dramatically.  Unlike skeletal muscle, the cardiac action potential is not initiated by neural 
activity, but rather modulated by it.  The heart contains two broad types of cells: 1) contractile 
and 2) conductile.  The contractile cells are those within the atria and ventricle responsible for 
the contraction of the myocardium.  Whereas, the conductile cells are specialized muscle cells 
involved in the initiation and propagation of action potentials and typically have little mechanical 
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capability.  These cells generally make up the sinoatrial (SA) and atrioventricular (AV) nodes 
along with the bundle of His and Purkinje cells. In the normal human heart, each heartbeat is 
driven by the primary pacemaker cells of the SA node, which initiates and then propagates the 
action potential across the atria, resulting in contraction of the atria.  Additionally, the AV nodal 
cells are activated and serve to spread the action potential to the ventricles via the bundle of His 
and Purkinje fibers.  While in healthy hearts, SA nodal cells are responsible for the automaticity 
of the heartbeat; all heart cells have the capability to generate a spontaneous action potential.  
Under normal conditions, SA nodal cells drive the heartbeat because they generate ~80-100 
action potentials/minute, which overrides the AV nodal cells and bundle of His with ~40-60 and 
15-30 action potentials/minute, respectively (3).  However, if the function of the SA nodal cells 
is lost, AV nodal cells or those of the bundle of His can keep the heart beating, although this 
results in the atria and ventricles beating independently of one another.  Under this condition, 
called complete heart block, usually the reduced ventricular rate is too slow to provide sufficient 
cardiac output for the body.  Additionally, while contractile cells typically do not have 
pacemaker activity, they can be induced (e.g. during ischemia) into spontaneous depolarizations, 
resulting in ectopic heartbeats.  Furthermore, neonatal ventricular cardiomyocytes, which are 
often used in research due to their plasticity, resemble a hybrid between conductile and 
contractile cells.  When cultured to form a syncytium they spontaneous beat similar to SA nodal 
cells.  Research has shown that these cells contain all of the primary ion channels needed for 
spontaneous activity and contraction, including the hyperpolarization-activated ‘funny’ channel 
(If), T-type and L-type Ca2+ channels, inward Na+ channels, and inward and outward K+ channels 
(4). 
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The roles of cationic currents (Na+, Ca2+, K+) in setting cardiac action potentials and in 
contraction rate have been well studied.  Figure 1.1 illustrates the individual roles of these 
cationic currents in generating cardiac action potentials.  In spontaneously beating rat ventricular 
myocytes, If has been shown to be critical in the generation of action potentials (5).  However, 
using SA nodal rabbit myocytes, Vinogradova et al found that high basal PKA activity and 
rhythmic oscillations in Ca2+ release from sarcroplasmic reticular stores contributed significantly 
to spontaneous beating (6).  Therefore, we see that spontaneous contraction rate is controlled by 
multiple processes involving ion channels, kinases, and Ca2+-signaling proteins.  
While cationic currents are typically seen as the “drivers” of contraction rate, anion 
currents (notably Cl-) have been less studied due to their perception as purely “modulators.”  
Despite their dwarfed status, roles for Cl- channels in action potentials have been investigated.  
Over the past 10 years, several extensive reviews examining the expression and function of Cl- 
channels in the heart have been published (7-16).  Similar to other cells, in cardiac myocytes, Cl- 
channels are expressed in the sarcolemmal membrane, sarcoplasmic reticular membrane, 
mitochondrial membranes, and nuclear membranes (17).   In the heart, most Cl- channels fall into 
four types, which consist of the outward-conducting Cl- channels (swelling-activated Cl- 
channels, Ca2+-activated Cl- channels, and the cystic fibrosis transmembrane conductance 
regulator), and inward rectifying Cl- channels.  As inward-rectifying Cl- channels have 
significantly distinct roles from outward-conducting Cl- channels, they will not be discussed 
here, rather we will focus our discussion on those channels which have potential functions most 
resembling CFTR. 
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NON-CFTR OUTWARDLY CONDUCTING CARDIAC Cl- CHANNELS 
Swelling-activated Cl- channels are important in maintaining the intracellular osmolarity 
and volume in response to changing extracellular environments.  While the molecular identity of 
this channel is controversial, its biophysical and regulatory characteristics are well understood.  
Similar to other cell types, in ventricular cardiomyocytes swelling-activated Cl- currents display 
moderate outward rectification, lack time-dependent activation upon depolarization, and are 
inhibited by tamoxifen, NPPB, and DIDS (18).  Activation of swelling-activated Cl- current is 
stimulated by changes in cell volume, osmolarity, membrane tension, and direct mechanical 
stretch.  Activation depends on the presence of intracellular ATP; however, no ATP hydrolysis is 
necessary (19, 20).  It has been suggested that the dependence on cytosolic ATP may serve to 
prevent the loss of metabolically valuable intracellular organic osmolytes during starvation (19, 
21).  Additionally, the activation of swelling-activated Cl- currents is modulated by the 
intracellular Cl- concentration, as high [Cl-]i shifted the set-point of activation to larger volumes 
or decreased the rate of activation (22-24). Because it is activated by mechanical stress, swelling-
activated current is considered a potential effector of mechanoelectrical feedback.  Swelling-
activated current is activated in ischemic and non-ischemic dilated cardiomyopathies and plays a 
role in arrhythmogenesis, myocardial injury, preconditioning, and apoptosis of myocytes (8).  
Electrophysiological analysis of Ca2+-activated currents in numerous cell types has 
shown that widely different single-channel conductances exist, ranging from 1 to 70 pS, 
suggesting a molecular diversity of Ca2+-activated Cl- channels (CaCC).  In ventricular 
myocytes, small 1 pS Ca2+-activated Cl- currents that are sensitive to niflumic acid and DIDS 
have been recorded (25, 26).  While these currents are typically outwardly rectifying and show 
time-dependent activation upon depolarization, as cytosolic Ca2+ concentrations increase, both 
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characteristics gradually decrease to almost time-independent activation and a linear I-V curve 
(27).  As the name suggests, Ca2+-activated currents are activated by increases in intracellular 
Ca2+ (Ca2+i), resulting from Ca2+ influx via voltage-gated Ca2+ channels and/or release of Ca2+ 
stores from the sarcoplasmic reticulum.  Additionally, CaCC are activated by phosphorylation 
from Ca2+-dependent kinases such as calmodulin-dependent kinase II (CaMKII) (28).  The 
importance of CaCC in appropriate action potential formation has been well described.  CaCC 
has been shown to be responsible for the early repolarization phase Ito2, which is 4-
aminopyridine-insensitive (28).  This was illustrated by Xu et al, who found that inhibition of 
CaCC by niflumic acid led to prolongation of the early repolarization of the cardiac action 
potential (26).   
In summary, it has been thought that outwardly conducting Cl- channels share a similar 
role in maintaining the resting membrane potential and minimizing action potential prolongation 
associated with stimulation of inward Ca2+ current.  As a result, these Cl- channels may be 
arrythmogenic and prevent hypercontraction through prevention of Ca2+i overload (10, 25, 29) 
(Figure 1.2). 
 
STRUCTURE AND ELECTROPHYSIOLOGICAL PROPERTIES OF CFTR 
Structure.  CFTR is a member of the family of ATP-binding cassette (ABC) 
transporters, the largest family of known ion channels.  Like other members of this family, CFTR 
is a 12 transmembrane protein with 2 membrane-spanning domains, each consisting of 6 
transmembrane motifs, with cytosolic N- and C-termini.  While no crystal structure for CFTR 
exists, based on amino acid sequence, hydropathy plots, and crystallization of related 
components (30), models of CFTR have been generated (Figure 1.3).  Extracellularly, CFTR is 
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heavily glycosylated.  Experiments examining CFTR variants lacking the consenses 
glycosylation sequences in the extracellular loop suggest that glycosylation is not necessary for 
correct protein processing or for the formation of a phosphorylation-regulated Cl- channel (31, 
32).  However, anion efflux by these mutations did alter the time course of channel activity, 
suggesting glycosylation may be involved in channel function (31).  The role of glycosylation in 
the maturation and function of CFTR and its relation to clinical disease remains an active area of 
investigation (33).  Intracellularly, CFTR consists of two nucleotide-binding domains (NBD) and 
a regulatory (R) domain.  The roles of these domains in CFTR physiology and pathophysiology 
are an area of intense investigation and are thoroughly reviewed elsewhere (34-36).  Briefly, like 
other ABC transporters, the NBDs of CFTR are responsible for ATP hydrolysis.  This hydrolysis 
by both NBDs controls both the opening and closing of CFTR channels.  However, ATP 
hydrolysis of NBDs is dependent upon phosphorylation of the R domain, which contains several 
phosphorylation sites.  Although CFTR is classically described as a “cAMP-stimulated” channel 
due to activation of CFTR by PKA, the R domain of CFTR contains multiple phosphorylation 
sites, which regulate its channel activity.  While cAMP/PKA-activation is generally believed to 
be the major form of activation, CFTR is also activated by PKC (in the presence and absence of 
Ca2+) (37) and cGMP/PKG (38).  In addition to these kinases, phosphorylation of the R domain 
is regulated by serine/threonine protein phosphatases, most notably PP2A (37).  The importance 
of NBDs in channel activity and the presence of multiple disease causing mutations within these 
regions has spurred a significant effort to understand the ways in which these NBDs affect CFTR 
channel function.  Additionally, as our understanding regarding the complex signaling pathways 
found in cells expands, so does our knowledge about the role of CFTR and its R domain. 
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 Electrophysiological properties.  Unlike many of the other ion channels found in the 
heart, CFTR is a voltage-independent channel.  Under symmetrical Cl- conditions, CFTR 
channels exhibit a linear I-V relationship, although in asymmetrical conditions, this can rectify.  
CFTR has been shown to have a low single-channel conductance of 6-10 pS (39, 40).  Reversal 
potential measurements with different NaCl gradients indicate that CFTR is selective for anions 
over cations.  In whole cell patch, the anion permeability of CFTR is Br-≥Cl->I->F- (41).  
However, in excised patches, the permeability sequence changes to I->Br->Cl->F-.  This 
discrepancy was explained by observations that I-, unlike other halides, blocks the pore of CFTR, 
thus rendering I- less permeable under whole cell conditions (42).  Additionally, CFTR is 
permeable to some polyatomic ions, such as  NO3-, HCO3-, formate, and acetate (in that order of 
permeability), but not others, including pyruvate, propanoate, methanesulfonate, ethanesulfonate, 
and gluconate (43).  CFTR has also been shown to be permeable to ATP (44) and glutathione 
(45), although the physiological significance of this is still under investigation.  While this data 
gives insights into the pore of the channel, it is well accepted that physiologically CFTR 
functions as an anion channel that conducts both Cl- and HCO3-. 
 
TISSUE DISTRIBUTION OF CFTR EXPRESSION 
 CFTR is broadly expressed throughout the body, including both epithelial and non-
epithelial tissues.  By far, CFTR has been most widely examined in epithelial tissues, where 
morbidity and mortality affecting cystic fibrosis patients, whom have decreased to no CFTR 
activity or expression, has classically most significantly affected epithelial tissues.  As a 
sampling, in humans, CFTR is expressed in the sweat glands, along the respiratory tract, 
gastrointestinal tract, and reproductive tissues.  Although less studied, it has also been 
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documented that CFTR is expressed in other tissue types, such as immune cells (46), bone (47), 
nervous tissue (48, 49), and muscle (smooth (50), skeletal (51), and cardiac).  In the heart, CFTR 
expression is well accepted in several animals, including rats (52), mice (53), guinea pigs (54), 
rabbits (55), swine (56), dogs (54), and primates (57).  In general, CFTR is predominantly 
expressed in ventricular myocytes, although it has been reported in atrial cells (57).  The story 
regarding CFTR expression in humans has received much debate, as conflicting reports exist.    
While Warth et al reported expression and activity of CFTR in human atrial myocytes (57); 
Berul et al found none (58).   In contrast, in human ventricular myocytes, multiple groups have 
found both expression and activity of CFTR, although it does appear to be expressed at levels 
significantly lower than epithelial cells (57, 59). 
 
CFTR FUNCTION 
By far CFTR is most widely regarded as a Cl- channel. In all tissues examined, CFTR has 
been shown to be an important ion channel in the homeostatic regulation of salts.  Depending on 
the tissue type, this may involve absorption of salts (e.g. sweat glands), while in others it 
involves secretion (e.g. intestines).  In cardiac myocytes, ions can move in either direction 
depending on the membrane potential.  Similar to swelling-activated and Ca2+-activated Cl- 
channels, it is has been postulated that CFTR serves as a regulator of cardiomyocyte membrane 
potential and action potential duration.  In recent simulation studies it was found that under β-
adrenergic stimulated conditions CFTR density altered the action potential duration along with 
the membrane potential (60) (Figure 1.4).  However, whether altered CFTR density or activity 
affects heart function experimentally has yet to be shown. 
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As mentioned previously, CFTR is not just a Cl- channel, but is also permeable to other 
anions, most notably HCO3-.  Beyond its role in salt regulation, CFTR also has a confirmed role 
in the regulation of pH.  CFTR can modulate extracellular and intracellular pH directly through 
its conductance of HCO3- (61, 62) or indirectly through its interactions (functional and/or 
physical) with Cl-/HCO3- exchangers (63, 64), Na+/H+ exchangers (65), carbonic anhydrase (66), 
and intacellular V-ATPases (46).  This, together with the potential roles of CFTR in ATP 
signaling (44) and redox regulation (45), highlights the importance of CFTR in physiological 
functions.  
 
CFTR AND CYSTIC FIBROSIS 
Cystic fibrosis (CF), with mutations in the gene coding for the anion conductance channel 
CFTR, epitomizes a disease whose clinical manifestations are due to defective ion transport.  As 
the most common lethal genetic disorder among Caucasians, CF affects nearly 30,000 
individuals in the U.S. per year (www.cff.org).  Since the discovery that the primary defect in CF 
involves mutations in the gene encoding for CFTR, extensive research efforts have been 
dedicated to characterizing the role of CFTR in the pathophysiology of CF. There are over 1,500 
mutations in CFTR that fall into one of five categories of mutations.  These mutations can cause 
a breadth of problems ranging from no production of CFTR RNA to abnormal CFTR 
conductance.  The classes of mutations and their phenotypes are summarized in Figure 1.5.  In 
Caucasians, the most abundant genotype is ∆F508 (deletion of phenylalanine at amino acid 508 
found in NBD1), occurring in greater than 50% of CF patients, which results in misfolding of 
CFTR and retention in the endoplasmic reticulum (Class II mutation).  While different mutations 
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can affect CFTR in a variety of ways, ultimately, the extent to which CFTR is functional 
correlates with degree of disease severity. 
While the majority of research and clinical efforts have focused on pulmonary and 
gastrointestinal complications, defects in additional systems, including endocrine (67), 
immunological (46), reproductive (68), muscular (50), and bone (47) have been identified and 
found to cause significant morbidity associated with CF. Likewise, there are reports of cardiac 
abnormalities in CF patients, including alterations in left ventricular function, ventricular 
arrhythmias, tachycardia, cardiomyopathy, myocardial fibrosis and necrosis (69-74).  
 
CONTROVERSY REGARDING CFTR IN THE HEART AND ITS RELATION TO 
CYSTIC FIBROSIS  
The electrophysiological evidence for CFTR being responsible for the PKA-stimulated 
Cl- channel in the heart is substantial.  Despite these findings, there is significant controversy 
regarding the functional significance of CFTR in heart function.  This controversy is a result of: 
1) low CFTR expression in human cardiac tissue (53, 59); 2) conflicting reports about the 
presence of CFTR currents in human cardiac tissue (58, 59, 75); and 3) rare clinical 
cardiovascular manifestations in CF patients (personal discussions with CF physicians). It is 
unclear whether the results with CFTR expression and currents are due to the difficulty in 
obtaining reliable tissue samples (diseased vs. non-diseased, atrial vs. ventricular), the 
reductionist methods employed (single-cell patch clamp), the age studied (pediatric vs. adult), or 
physiological factors.  Even though CFTR expression and current in cardiomyocytes appears to 
be small in contrast to epithelial cells, small changes in conductance in the heart can lead to 
significant changes in current and function.  When examined in more physiological settings, 
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several studies have found CFTR involved in physiological events (e.g. ischemia) experienced 
by heart (76, 77).  In particular, a recent study examining ABC transporters in ventricular tissue 
from humans found that CFTR is significantly down-regulated in individuals who have 
experienced heart failure (78).  While documentation of cardiovascular complications in CF 
patients is sparse, it is present.  In living individuals several studies have been conducted to 
evaluate potential cardiac defects in CF patients.  Collectively, these studies have found that 
cardiac abnormalities can be detected in CF patients, including alterations in left ventricular 
function, ventricular arrhythmias, tachycardia, and cardiomyopathy (69, 71-74).  Additionally, 
post-mortem analysis of CF patients found myocardial fibrosis and necrosis in a set of CF 
patients that had died from sudden cardiac arrest (70).  Therefore, while CFTR is clearly not an 
absolutely necessary protein for cardiac function (as CF patients do live), the role of CFTR in the 
heart remains unknown.  As therapies for CF continue to improve and patients begin to lead 
longer, more active lives, it becomes imperative to determine whether the observed cardiac 
abnormalities found in CF patients are due to primary cardiac defects or are secondary due to 
their lung dysfunction.  These findings will establish if CF patients are at increased risk for heart 
disease.  
 
SPECIFIC AIMS 
Broadly, the aims of this dissertation are to first determine if CFTR plays a role in cardiac 
physiology or exists as a redundant protein and then to explore the mechanism(s) in which CFTR 
may fulfill its role.  Additionally, the focus of this work is to understand how cardiac function 
may be impacted by loss of CFTR activity, as is found in CF.  While multiple components are 
involved in cardiac function we have chosen to investigate its potential role in cardiomyocyte 
 12 
contraction rate.  We feel that the aims outlined below, which will utilize a spectrum of 
physiological and cell biology techniques, will answer these basic questions and set a foundation 
for future areas of investigation. 
Aim 1: To determine if CFTR plays a role in the regulation of un-stimulated and β-
adrenergic stimulated cardiomyocyte contraction rate and understand how acute and chronic 
loss of CFTR affects cardiomyocyte contraction rate. 
Aim 2: To begin to understand the way in which CFTR may functionally interact with 
other cardiac proteins, we will examine the potential role of MRP4 in cardiomyocyte contraction 
rate and determine if CFTR is involved in mediating functional responses to cAMP-modulating 
proteins, such as MRP4 and PDE4. 
Aim 3: To further understand the role of CFTR in heart function, we will compare the 
structure and in vivo function of adult hearts from wildtype and CFTR knockout mice  
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Figure 1.1.  Currents responsible for SA nodal (A) and ventricular action potentials (B).  
Figures were taken from Opie (3).  A.  “Transient ICa” refers to T-type Ca2+ channels and “long-
lasting ICa” refers to L-type Ca2+ channels.  B.  “Na/Ca” refers to the Na+/Ca2+ exchanger. 
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Figure 1.2.  Roles of outwardly conducting Cl- currents on β-adrenergic stimulated action 
potentials.  A.  General effect of Cl- removal on action potential duration (3).  B and C.  Role of 
swelling-activated and Ca2+-activate Cl- channels on cardiac action potentials, respectively.  Top 
represents action potential and bottom represents actual current.  Black lines indicate normal 
action potential with red lines indicating effect of current loss (7). 
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Figure 1.3.  Schematics and models of CFTR structure.  A. Schematic representation of 
CFTR, modified from 
http://physpharm.ohsu.edu/faculty/Dawson%20Lab/Dawson%20Lab%20Homepage.htmlB.   
Artist rendering of CFTR (79).  C.  Theoretical model of CFTR, modified from Serohijos et al 
(80). 
A 
B 
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Figure 1.4.  Simulation of action potential duration and membrane potential during β-
adrenergic stimulation with various densities of CFTR.  Thick black, thin black, and gray 
lines represent the data obtained with 1x, 3x, and 5x CFTR densities, respectively.  Figure taken 
from Kuzomoto et al (60). 
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Figure 1.5. Representation of the types of CFTR mutations associated with cystic fibrosis.  
Taken from http://www.cysticfibrosismedicine.com/htmldocs/CFText/genetics.htm 
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CHAPTER 2: 
CFTR IN THE REGULATION OF CARDIOMYOCYTE CONTRACTION RATE AND 
COMPENSATORY ROLES OF CAMKII AND Ca2+-ACTIVATED Cl- CHANNELS 
 
ABSTRACT 
In ventricular cardiomyocytes the cystic fibrosis transmembrane conductance regulator (CFTR) 
has been extensively studied using electrophysiological techniques, however, there is a paucity 
of data regarding its physiological function.  Using spontaneously beating neonatal ventricular 
cardiomyocytes from wildtype or CFTR knockout (KO) mice, we examined the role of CFTR in 
the modulation of cardiomyocyte contraction rate.  Contraction rates of spontaneously beating 
myocytes were captured by video imaging.  Real-time changes in Ca2+i and PKA activity were 
measured by Fura-2 and fluorescence resonance energy transfer, respectively.  Additionally, 
phosphorylation of phospholamban at threonine 17 (PLB-Thr17) was measured by Western blot.  
Pharmacological inhibition of CFTR by CFTRinh-172 resulted in a transient inhibition of 
contraction rate, whereas CFTR KO mice displayed normal contraction rates.  Further 
investigation revealed that acute loss of CFTR activity results in a transient increase in Ca2+i via 
L-type Ca2+ channel activation, resulting in inhibition of PKA activity.  Additionally, we found 
that contraction rate normalization from acute CFTR inhibition or chronic deletion relies on 
activation of Ca2+/calmodulin-dependent kinase II (CaMKII) and Ca2+-activated Cl- channels 
(CaCC) as simultaneous addition of myristoylated-autocamtide-2-related inhibitory peptide or 
niflumic acid, with CFTRinh-172 or in CFTR KO mice resulted in sustained attenuation of 
contraction rates.  CFTRinh-172 also caused significant alterations in PLB-Thr17 
phosphorylation.  Our results indicate that CFTR is involved cardiomyocyte contraction 
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regulation, however, loss of CFTR is compensated by activation of CaMKII and CaCC.  
Increased dependence on CaMKII upon loss of CFTR may leave cystic fibrosis patients at an 
increased risk for heart dysfunction and disease. 
 
INTRODUCTION 
To sustain proper physiological function, the heart maintains tight control of ion channels 
and transporters.  Four major Cl- currents have been described in the heart, including the cystic 
fibrosis conductance regulator (CFTR), Ca2+-activated Cl- channels (CaCC), swelling-activated 
Cl- channels, and inward rectifying Cl- channels.  As outwardly conducting channels, it has been 
thought that CFTR, swelling-activated Cl- channels, and CaCC share a similar role in 
maintaining the resting membrane potential and minimizing action potential prolongation 
associated with stimulation of inward Ca2+ current.  As a result, these Cl- channels may be 
arrythmogenic and prevent hypercontraction through prevention of Ca2+i overload (1-3). 
Shortly after the identification of the CFTR gene from epithelia, a cAMP- or PKA-
dependent Cl- channel resembling CFTR was identified in cardiomyocytes (4).  Subsequently, 
expression of a cardiac-specific isoform of CFTR (cCFTR) was reported in atrial and ventricular 
myocytes of numerous species, including human (5-8).  This isoform arises from alternative 
splicing, resulting in loss of a portion of the first intracellular loop, but otherwise retains >95% 
sequence homology to epithelial CFTR.  cCFTR behaves similarly to epithelial CFTR and is 
activated and inhibited by the same agents that affect epithelial CFTR.  Additionally, clinical 
mutations of CFTR, which cause the disease cystic fibrosis (CF), lie outside of this region.  
While no clear physiological role for CFTR in the heart has been firmly established, it has been 
suggested that, as a Cl- channel, CFTR may be involved in the autonomic regulation of action 
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potential duration and minimize the action potential prolongation associated with β-adrenergic 
stimulation, similar to the other outwardly conducting cardiac Cl- channels mentioned previously 
(9).  Studies showing that CFTR is up-regulated during ischemia (10) and that CFTR KO mice 
lose the protection of ischemic preconditioning (11), suggest the importance of CFTR in 
maintaining healthy cardiomyocytes during physiological events experienced by the heart.  
While the aforementioned studies have provided important insight into potential roles of CFTR 
in the heart, we still lack a full understanding regarding the physiological role(s) of CFTR and 
the mechanism(s) employed to fulfill its functions. 
In an attempt to further understand the role(s) of CFTR in cardiac physiology, we 
examined the potential role of CFTR in the regulation of ventricular cardiomyocyte contraction 
rate and the impact of its loss.  Our data show that CFTR is involved in the regulation of 
cardiomyocyte contraction rate, however, acute or chronic loss of CFTR can be compensated for 
by activation of Ca2+/calmodulin-dependent kinase II (CaMKII) and Ca2+-activated Cl- channels 
(CaCC).   Acute loss of CFTR causes activation of L-type Ca2+ channels, resulting in Ca2+-
dependent inhibition of PKA activity and subsequent activation of CaMKII and CaCC, which are 
required for contraction rate recovery.  Similarly, we found that CFTR KO mice retain normal 
contraction rates through an increased dependence on CaMKII and CaCC activities.  
Illuminating the role of CFTR in cardiomyocyte physiology will enhance our knowledge 
regarding normal cardiac processes, while understanding the effects of loss of CFTR activity on 
cardiac processes will help to determine if CF patients are at increased risk for cardiac defects. 
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MATERIALS AND METHODS 
Ethical approval of animal use. FV/B mice were obtained from Charles River 
Laboratory (Wilmington, MA) and used for generation of wildtype (WT) mice.  CFTR KO mice 
(strain 2515 B6.129S6-Cftrtm1Kth/J) were initially obtained from Dr. Deborah Nelson at the 
University of Chicago (Chicago, IL) and bred in-house.  All animals were used within 24 hours 
of birth.  In the current study a total of 191 WT and 54 CFTR KO mice were used.  Use of 
animals was approved by the University of Illinois at Urbana-Champaign IACUC. 
Isolation and culture of neonatal mouse cardiomyocytes. Ventricular myocytes were 
cultured from neonatal mice for all experiments using a similar protocol as previously reported 
(12).  Freshly born mice were sacrificed by decapitation with surgical scissors.  Decapitation was 
used so that isolated myocytes would not be affected by anesthetics or altered environment 
(redox and pH (CO2)).  This procedure is justified to yield viable myocytes after isolation as both 
sedation and anesthetics significantly reduce the survival rate of isolated heart cells from 
neonates.  Decapitation of neonates avoiding prior anesthesia is done in compliance with the 
Report of the AVMA Panel on Euthanasia JACMA, Col 218, No. 5, March 1, 2001 p 682-3 
(http://www.avma.org/resources/euthanasia.pdf), and the NIH ARAC Guidelines for the 
Euthanasia of Mouse and Rat Fetuses and Neonates 
(http://oacu.od.nih.gov/ARAC/euthmous.htm).  Neonatal mouse cardiac tissue devoid of atria 
were exposed to enzymatic digestion.  Subsequently, isolated cells were pipetted onto 35 mm 
Petri dishes pre-coated with 1.5% gelatin type A or laminin. Cells were plated at high- and low-
density for measurement of contraction rate or real-time imaging experiments, respectively.  
High-density plating allowed for cells to form a syncytium, whereas low-density plating 
facilitated individual quiescent myocytes.  Quiescent myocytes were used for imaging 
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experiments to eliminate any confounding effects from signaling associated with the action of 
contraction.  Cells were incubated at 37°C for 2-3 days until they displayed appropriate myocyte 
morphology or formed a syncytium for contraction rate measurements. Culture media 
(containing serum and 20 mM HEPES for buffering) was replaced daily and at least 1 hour prior 
to experiments.  
Measurement of contraction rate. Measurement of myoctye contraction rate was 
performed as previously reported (13).   35 mm dishes were placed in a temperature/CO2 
regulated apparatus.  Using a CCD camera and MetaMorph imaging software, 5-second video 
images were obtained every 2 minutes.  Following acquisition, a specific point within the field 
was selected and analyzed for movement in each x, y, and z plane.  Movements in the x and y 
plane were calculated and number of deflections noted as number of contractions. Each data 
point represents a single observation from different experiments so that only one data set was 
obtained from each experiment.  Each drug was tested using multiple isolations to ensure that the 
observed responses were not particular to a single isolation. 
Measurement of Ca2+i.  Quiescent ventricular myocytes were cultured at low-density as 
described above.  Upon formation of myocyte morphology (24-48 hours after culture), culture 
media was removed and cells were washed with 1X dulbecco’s phosphate buffer solution 
(DPBS).  After which cells were loaded with 5 µM Fura-2 AM dissolved in 0.01% Pluronic F-
127 plus 0.1% DMSO in DPBS at room temperature for 30 minutes.  Following loading, cells 
were washed with 1X DPBS or Ca2+-free DPBS (with EGTA (500 µM) to remove residual free 
Ca2+) and allowed to sit for 30 minutes to remove any unloaded dye and allow for complete de-
esterification of Fura-2 AM into Fura-2, its active form.  For Ca2+-free experiments, experiments 
were performed in Ca2+-free DPBS with EGTA.  Changes in Ca2+i were monitored by Fura-2 
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excitation at 340nm and 380nm and emission at 500nm. As the ratio of the light emitted at 
340nm excitation to that emitted at 380nm excitation (340/380 ratio) is a direct index of the level 
of Ca2+i, data is expressed as the 340/380 ratio following subtraction of background fluorescence. 
Measurement of real-time PKA or cAMP activity via fluorescent resonance energy 
transfer (FRET).  Following 24 hours in culture, neonatal cardiomyocytes were infected with 
an adenovirus containing AKAR2.2 (PKA) or ICUE3 (cAMP) (100 MOI, 24 hours) in a similar 
manner as previously published (14).  24-48 hours post-infection cells were washed and stored in 
DPBS for FRET recordings.  Dual emission ratio imaging was acquired for 200 seconds at 20-
second intervals.  Images in both channels were subjected to background subtraction and ratios 
of yellow-to-cyan were calculated at different time points and then normalized to baseline 
signals.  For AKAR2.2, phosphorylation of the PKA consensus site leads to an increase in the 
YFP/CFP ratio (14), whereas the binding of cAMP to the EPAC site of ICUE3 causes a decrease 
in FRET (15). 
Measurement of phospholamban phosphorylation.  Neonatal cardiomyocytes, 
pretreated with 20 µM CFTRinh-172 for various times, were chilled, washed, and harvested in 
lysis buffer (20 mM Hepes pH 7.5, 2 mM EDTA pH 8.0, 150 mM NaCl, 10% Glycerol, 0.6% 
NP4O, 20 mM Na4P2O7, 50 mM NaF, 2.5 mM Na3VO4 and Protease Inhibitor Single-Use 
Cocktail (Thermo Scientific, PIERCE)). The lysates were clarified at 13,200 x g for 20 minutes 
at 4° C. The samples were resolved on a SDS-PAGE gel. Phospholamban phosphorylation was 
detected with a phospho-Threonine 17 antibody (PLB-Thr17, Badrilla, UK).  Additionally, total 
phospholamban was probed with an anti-phospholamban antibody (PLB, Badrilla, UK) and γ-
tubulin with an anti-γ-tubulin antibody (Sigma, MO). Primary antibodies were visualized with 
IRDye 680CW goat anti-mouse or with IRDye 800CW goat anti-rabbit secondary antibodies 
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using an Odyssey scanner (Li-cor biosciences, NE).  The signals obtained from PLB-Thr17 were 
corrected and plotted as the increase over internal control (γ-tubulin). 
Chemicals.  Niflumic acid, thapsigargin, and myristoylated-PKA inhibitor fragment 14-
22 (PKI) were obtained from Sigma-Aldrich (St. Louis, MO).  CFTRinh-172 and BayK-8644 
were obtained from Calbiochem (San Diego, CA) and Cystic Fibrosis Foundation Therapeutics 
(CFTRinh-172 only)(Chicago, IL).  Myristoylated-autocamtide-2-related inhibitory peptide (AIP) 
was obtained from Biomol (Plymouth Meeting, PA).  Fura-2 AM was purchased from Invitrogen 
(Carlsbad, CA).  Ryanodine came from Alomone Labs (Jerusalem, Israel).  Niflumic acid, 
CFTRinh-172, ryanodine, thapsigargin, and Fura-2 AM were dissolved in DMSO, while PKI and 
AIP were dissolved in water.  All drugs were made as 1:1000 stock solutions and diluted the day 
of the experiment.  
Statistical analysis.  For presentation of changes in contraction rate, Ca2+i, or PKA 
activity, peak responses were subtracted from their respective baseline values.  For percentage 
baseline measurements, the last measured contraction rates were divided by baseline values. 
Normalization was performed by GraphPad Prism software by setting the first baseline 
measurement to 100% and the value of 0 to 0%. For comparison between two groups of data, 
student’s t-test was used to determine significance.  For multiple comparisons, one-way analysis 
of variance (ANOVA) was performed.  Comparison of time course curves were performed by 
two-way ANOVA.  Results were considered significant at P < 0.05 and are denoted accordingly. 
 
RESULTS 
Effect of pharmacological inhibition and genetic deletion of CFTR on 
cardiomyocyte contraction rate.  To examine the potential role of CFTR in the regulation of 
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ventricular cardiomyocyte contraction rate, we used syncytial neonatal ventricular myocytes, 
which form a single spontaneously beating unit.  In control experiments (DMSO or H2O) we 
found that cardiomyocytes held a steady rhythm of beating over time (Figures 2.1, 2.4, 2.5).  To 
determine the effect of CFTR inhibition on cardiomyocyte contraction rate, we used the selective 
CFTR inhibitor, CFTRinh-172.  Application of CFTRinh-172 (10 and 20 µM) resulted in a 
transient, but significant (P < 0.05), dose-dependent inhibitory effect of contraction rate that 
subsequently returned to baseline levels (Figure 2.1).  Addition of CFTRinh-172  (20 µM) to 
CFTR KO myocytes produced no significant inhibition of contraction rate compared to baseline 
or DMSO (P > 0.05), indicating specificity of action of CFTRinh-172 and the ability of CFTR KO 
cardiomyocytes to function normally without CFTR.  Thus, we found that CFTR is involved in 
the physiological regulation of cardiomyocyte contraction rate; however, both acute and chronic 
loss of CFTR activity can be compensated for. 
Effect of CFTRinh-172 of Ca2+i and real-time PKA activity.  Previously, the 
contraction rate of spontaneously beating cardiomyocytes has been shown to be dependent on 
changes in Ca2+i and PKA activity (16).  Therefore, in an effort to understand the mechanism 
whereby CFTR inhibition causes a transient inhibition in cardiomyocyte contraction rate we 
investigated if CFTRinh-172 alters Ca2+i and/or PKA activity.  We first examined Ca2+i by 
monitoring changes in Fura-2 fluorescence, which is a direct index of Ca2+i, in WT and CFTR 
KO mice.  In WT mice, CFTRinh-172 (20 µM) caused a significant increase in Ca2+i compared to 
DMSO treated myocytes (P < 0.001) (Figure 2.2A).  In contrast, in CFTR KO mice CFTRinh-172 
failed to elicit a significant increase in Ca2+i compared to DMSO (P > 0.05).  To understand the 
source of this Ca2+i increase we performed additional experiments targeting extracellular and/or 
intracellular Ca2+ stores and the channels/transporters responsible for our observed effects.  As 
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seen in Figure 2.2B, removal of extracellular Ca2+ completely prevented the CFTRinh-172 
induced increase in Ca2+i.  In contrast, inhibition of sarcoplasmic reticulum Ca2+ release by 
pretreatment with thapsigargin (1 µM) & ryanodine (10 µM) prior to CFTRinh-172 did not have 
any significant influence on Ca2+i changes from CFTRinh-172.  While many routes of Ca2+ entry 
in cardiomyocytes exist, L-type Ca2+ channels and the Na+/Ca2+ exchanger are the most 
prominent.  Therefore, we examined if one or both of these proteins are involved in mediating 
CFTRinh-172 induced increases in Ca2+i.  Pretreatment with the L-type Ca2+ channel inhibitor 
nifedipine (10 µM), but not the Na+/Ca2+ exchange inhibitor KB-R7943 (10 µM) completely 
prevented CFTRinh-172-induced increases in Ca2+i.  Thus, these data indicate that inhibition of 
CFTR causes L-type Ca2+ channel activation resulting in a transient increase in Ca2+i. 
Subsequently, we sought to determine the effect of CFTRinh-172 on PKA activity.  To do 
this, we utilized FRET to monitor real-time PKA activity.  Compared to DMSO, CFTRinh-172 
(20 µM) resulted in a significant inhibition of PKA activity, both in magnitude and time (P < 
0.001)(Figure 2.3A).  This inhibition was transient and recovered to baseline levels within 20 
minutes, resembling the pattern of inhibition observed on contraction rates.  This effect was not 
the result of upstream alterations in adenylyl cyclase activity as separate experiments measuring 
cAMP showed that CFTRinh-172 caused no change in cAMP levels (0.17 ± 0.02 vs. 0.20 ± 0.01 -
∆YFP/CFP, P > 0.05 vs. DMSO).  To understand how CFTR inhibition leads to a decrease in 
PKA activity we examined if there was a link between the previously observed Ca2+i change and 
PKA activity.  In these experiments, inhibition of the L-type Ca2+ channel with nifedipine 
pretreatment (10 µM) completely prevented CFTRinh-172-induced attenuation of PKA activity 
(Figure 2.3B), indicating that activation of L-type Ca2+ channels was responsible for CFTRinh-
172-induced inhibition of PKA activity.  Similarly, direct activation of L-type Ca2+ channels by 
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BayK-8644 (1 µM) caused a significant decrease in PKA activity, providing further evidence 
that L-type Ca2+ activation can negatively affect PKA activity.  To verify that inhibition of PKA 
activity would directly lead to functional attenuation of contraction rate, we examined the effect 
of PKI (20 µM), a selective peptide inhibitor of PKA, on cardiomyocyte contraction rate.  In 
agreement with previous reports (14, 16), we found that PKA inhibition caused a significant 
decrease in contraction rate (P < 0.001)(Figure 2.3C).  In separate experiments, we found that 
direct activation of L-type Ca2+ channels by BayK-8644 (1 µM) also led to a significant 
inhibition of contraction rate (-133 ± 5 ∆beats/min, P < 0.001 vs. H2O, n = 6).  Taken together 
with our previous findings, these results indicate that inhibition of CFTR causes a transient 
increase in Ca2+i via activation of L-type Ca2+ channels and that this causes a transient inhibition 
of PKA activity, thereby leading to a decrease in contraction rate. 
CaMKII in the recovery of CFTRinh-172-induced contraction rate depression.  
Previously it has been shown that PKA and CaMKII regulate overlapping signaling cascades 
leading to complimentary regulation of proteins (i.e. phospholamban) involved in cardiomyocyte 
contraction (17).  With our observed increase in Ca2+i, we sought to determine if CFTR 
inhibition altered CaMKII activity.  We first examined the effect of CaMKII inhibition on 
cardiomyocyte contraction rate.  In WT mice, addition of AIP (1 µM), a selective CaMKII 
inhibitor, alone reproducibly caused a minor, statistically insignificant (P > 0.05) decrease in 
contraction rate compared to control (Figure 2.4A).  However, in separate experiments, when we 
added CFTRinh-172 (20 µM) together with AIP, cardiomyocyte contraction rate was not able to 
recover to baseline in a manner comparable to CFTRinh-172 alone (Figure 2.4B).  To further 
examine this we measured the effect of CFTRinh-172 on PLB-Thr17 phosphorylation, a specific 
CaMKII phosphorylation site on phospholamban.  In agreement with our functional data, 
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CFTRinh-172 (20µM) caused a significant increase in PLB-Thr17 phosphorylation (Figure 2.4C).  
This phosphorylation occurred very rapidly (within 2 minutes) and was transient as 
phosphorylation returned to near-baseline levels within 4 minutes.  Thus, while CFTRinh-172 
induces a transient increase in Ca2+i that causes a decrease in contraction rate, it also causes 
activation of CaMKII, which facilitates recovery from CFTR inhibition.  To determine if 
CaMKII is also important under conditions of chronic CFTR loss, we examined the effect of 
CaMKII inhibition in CFTR KO mice.  As seen in Figure 2.4D, inhibition of CaMKII by AIP 
produced a profound inhibitory effect on CFTR KO contraction rate.  This effect was 
significantly enhanced from the effect of AIP on WT cardiomyocytes (Figure 2.4E). Therefore, 
whereas CFTR KO cardiomyocytes produce normal contraction rates, they appear to have an 
increased dependence on CaMKII activity to maintain these rates. 
Role of CaCC in the regulation of cardiomyocyte contraction rate.  Subsequently we 
sought to determine how CaMKII activation could facilitate an increase in contraction rate for 
recovery from CFTR inhibition.  Due to the transient nature of PLB-Thr17 phosphorylation we 
propose that this recovery was not purely a result of altered PLB phosphorylation.  It has been 
widely shown that loss of CFTR activity can lead to increased activation of CaCC as a 
compensatory Cl- conductive pathway(18). With our observations that CFTR inhibition increases 
Ca2+i and CaMKII activity, we sought to determine if activation of CaCC could compensate for 
loss of CFTR activity.  To investigate CaCC in cardiomyocyte contraction rate regulation, we 
used niflumic acid (100 µM) to directly inhibit CaCC.  Addition of niflumic acid alone resulted 
in a rapid, but transient, decrease in contraction rate, which recovered to baseline (Figure 2.5A).  
Thus inhibition of either CFTR or CaCC resulted in similar functional effects on cardiomyocyte 
contraction rate indicating that, in ventricular cardiomyocytes, CFTR and CaCC may have 
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complimentary roles.  To determine if CaCC activity is necessary for recovery from CFTR 
inhibition, we performed experiments in which we simultaneously applied niflumic acid (100 
µM) and CFTRinh-172 (20 µM).  We found that inhibition of both CFTR and CaCC resulted in 
an initial abolishment of contraction rate, which was no longer able to fully recover to baseline 
(Figure 2.5B).  Subsequent examination of CaCC inhibition in CFTR KO mice also showed a 
significant inhibitory effect of niflumic acid on cardiomyocyte contraction rate.  Similar to AIP, 
the inhibitory effect of niflumic acid in CFTR KO mice was significantly enhanced to that in WT 
mice (Figure 2.5C and 2.5D), indicating an increased reliance on CaCC.  These results indicate 
that CaCC are important in recovery from CFTR inhibition and constitute an important 
downstream effector of CaMKII activation. 
 
DISCUSSION  
Since the first electrophysiological recording of CFTR in the heart in 1992 (19), there has 
been little dispute regarding it being responsible for the PKA-stimulated Cl- channel in the heart.  
While there have been conflicting reports about CFTR expression and/or activity in humans (20-
22), it has been found that CFTR is expressed and electrophysiological recordings made from 
rats (23), guinea pigs (24), rabbits (25), swine (26), dogs (24), primates (21), and most pertinent 
to our study, mice (27).  Despite these studies, questions remain regarding the role of CFTR in 
the heart.  Thus, the primary goal of our study was to determine if CFTR plays a physiological 
role in the regulation of heart function.  Using a selective pharmacological inhibitor of CFTR we 
have shown that CFTR does play an active role in the regulation of heart function, as measured 
by CFTRinh-172 induced depression of cardiomyocyte contraction rate.  These results are in 
agreement with cardiomyocyte simulation studies which showed that decreased CFTR current 
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density would lengthen action potential duration (28).  In our study we found that inhibition of 
CFTR causes a transient increase in Ca2+i due to activation of L-type Ca2+ channels, whose 
importance in action potential duration and contraction regulation are well established.   Future 
dissection of the nature of the interactions (i.e. direct or indirect) between CFTR and L-type Ca2+ 
channels may provide important insights into the regulation of cardiomyocyte contraction.   
In addition to alterations in Ca2+i, we have also shown that CFTR inhibition leads to a 
transient decrease in PKA activity, as measured by A-kinase activity receptor (AKAR) 
phosphorylation.  This study, along with others’ (14, 16), have shown that PKA is an important 
regulator of contraction.  We did not attempt to dissect out the exact mechanism whereby CFTR 
inhibition leads to PKA inhibition, however, we did show that this inhibition was caused by L-
type Ca2+ channel influx.  Cardiac myocytes contain Ca2+-sensitive adenylyl cyclases (AC5, 
AC6) that can be inhibited by increases in Ca2+i (29).  However, our findings that cAMP remains 
unchanged following CFTR inhibition rules out this possibility.  One possibility is that Ca2+-
sensitive phosphatases, such as calcineurin, are involved in the inhibition we observed. It has 
been shown that calcineurin antagonizes PKA activity through dephosphorylation of PKA 
effectors (30) and even direct inhibition of PKA itself (31).  Additionally, with the lack of effect 
on cAMP, we would argue that CFTR inhibition likely does not alter hyperpolarization cyclic-
gated nucleotide channels (HCN, If), which are known to be involved in contraction rate 
regulation (unpublished results)(32); although we cannot rule out an indirect effect of membrane 
potential alterations.  Altogether, we have documented how an inhibition of CFTR activity can 
alter ion channel and intracellular signaling activities to affect cardiomyocyte function. 
However, importantly, we found that CFTR-dependent depression of contraction rate was 
transient and was restored to normal rates.  Additionally, we found that CFTR KO mice 
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displayed normal contraction rates, further indicating that CFTR activity or expression is not 
critical to maintaining cardiomyocyte function. The fact that CFTR is not critical to maintaining 
baseline contraction rate is not surprising given that mutations in CFTR do not lead to early 
embryonic death in CF patients or mice.  The ability of cardiomyocytes to compensate for 
transient or long-term loss of CFTR does not discount its significance, but rather underscores the 
adaptability of the heart to maintain its vital function.  It is well accepted that gene knockout 
causes adaptation, but we have shown that short-term and chronic inhibition of CFTR leads to 
compensation in cardiac myocytes.  In our current study we have found that CaMKII and Ca2+-
activated Cl- channel (CaCC) activity was necessary for recovery from acute CFTR inhibition 
and maintenance of normal contraction rates in CFTR KO mice.  An interplay between CFTR 
and CaCC has been noted in several tissue types that express both channels.  In the airway, loss 
of CFTR, either in CF patients or CFTR KO mice, leads to increased activity of CaCC to 
compensate for loss of CFTR-dependent Cl- current (33).  Additionally, in bovine pulmonary 
artery endothelial cells, Xenopus oocytes, and mouse parotid acinar cells, expression of CFTR 
leads to a negative regulation of CaCC (33). While the CaCC inhibitor we used, niflumic acid, is 
a well-documented inhibitor of CaCC (33), it is not specific as previous studies have shown that 
niflumic acid can also affect CFTR (34) and K+ channels (35, 36).  While we cannot rule out 
effects on non-CFTR targets, our data showing that niflumic acid causes significant inhibition of 
contraction rate in CFTR KO mice makes us confident that our results are not due to additional 
effects on CFTR.  This coupled with the involvement of Ca2+i and CaMKII, both ways in which 
CaCC are activated, strengthens our view about the importance of CaCC during loss of CFTR 
activity.  However, since Ca2+ and CaMKII can also affect many other ion channels and kinases 
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important in contraction, it is necessary to further explore how CFTR inhibition in cardiac 
myocytes may affect other cellular components. 
CaMKII has been identified as an important intracellular signaling molecule in cardiac 
myocytes involved in regulating numerous cellular processes, including activation of ion 
channels, modulation of action potential, hypertrophy, and apoptosis (37).  In our study we found 
that CaMKII is important in the recovery of cardiomyocyte contraction rate caused by inhibition 
of CFTR.  Its role in this process appears to be, in part, due to its ability to activate CaCC, as 
inhibition of CaCC or CaMKII prevented recovery from CFTR inhibition.  CaMKII has also 
been shown to decrease the inactivation rate of L-type Ca2+ channels (38), which may aid in 
contraction rate recovery.  Another important finding is that, while CFTR KO mice display 
normal baseline contraction rates, in the presence of CaMKII inhibition, these rates were 
severely diminished.  In contrast, CaMKII inhibition in WT mice showed only minimal 
inhibition of baseline contraction rate.  These data indicate that CFTR KO mice have an 
increased dependence on CaMKII.  These findings are of particular interest, as cardiac myocytes 
with increased expression or activity of CaMKII are prone to pathological cardiac conditions. 
CaMKII has been linked to heart failure; hearts from mice with heart failure have increased 
expression of CaMKIIδ and overexpression of CaMKII causes heart failure in mice (39, 40).  In 
addition to heart failure, increased CaMKII activity may lead to prolonged action potential 
duration and cause long QT syndrome by increasing late-inactivating or slowly inactivating Na+ 
currents (41).  At this time we cannot say whether the increased dependence on CaMKII is due to 
long-term loss of CFTR activity or loss of CFTR protein, however, it would be intriguing to 
determine whether CFTR mutations, such as ∆F508 or G551D, which cause decreased protein 
expression due to abnormal folding or decreased CFTR gating, respectively, also display 
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increased dependence on CaMKII activity.  Thus, our findings coupled with those by Solbach et 
al that CFTR is downregulated in ventricular tissue from heart failure patients (42), and several 
observations that heart damage occurs in some CF patients (43, 44) warrants future investigation 
of the role of CaMKII in CF hearts.  
As the most common lethal genetic disorder among Caucasians, CF affects nearly 30,000 
individuals per year in the U.S. (www.cff.org).  Since the discovery that the primary defect in CF 
involves mutations in the gene encoding for CFTR, extensive research efforts have been 
dedicated to characterizing the role of CFTR in the pathophysiology of CF. In addition to the 
classic systems affected in CF (pulmonary, gastrointestinal, reproductive) recent evidence has 
shown that CFTR defects lead to pathologies in other organs, including muscle and bone. 
Likewise, there have been scattered reports of cardiac abnormalities in CF patients, including 
alterations in left ventricular function, tachycardia, cardiomyopathy, myocardial fibrosis and 
necrosis (45-48).  More recently it was found that 51% of CF patients with severe lung infection 
had significantly decreased ejection fraction during exercise (49).  It is unclear whether these are 
due to primary cardiac defects or secondary effects from altered pulmonary function.  The use of 
CFTR KO mice may be advantageous in this pursuit as they display a normal pulmonary 
phenotype, thus allowing dissection of primary vs. secondary effects of loss of CFTR.  The 
physiological relevance of CFTR in the heart requires investigation as recent advances in 
therapies for CF have extended the average lifespan of CF patients to the mid-30’s, with some 
individuals with milder mutations achieving normal life spans (70-80 years).  Therefore, it is 
likely that as therapeutic advances continue to be made and individuals live longer, more active 
lives, CF patients will enter the age range where cardiovascular abnormalities become apparent 
and may exhibit significant clinical cardiac symptoms.  A more complete understanding of the 
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role of CFTR in the heart may lead to the identification of potential cardiac defects in CF 
patients and thus increase the quality of care for these patients. 
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1.  Pharmacological inhibition, but not genetic deletion, of CFTR attenuates 
cardiomyocyte contraction rate.  A.  Syncytial WT ventricular myocytes were treated with 
DMSO (n ≥ 6), or CFTRinh-172 (10 µM or 20 µM, n = 7 each) for 20 minutes following a 10-
minute baseline.  Separately, the effect of CFTRinh-172 (20 µM, n = 5) on ventricular myocytes 
obtained from CFTR KO mice was also examined.   *, P < 0.05; **, P < 0.01; ***, P < 0.001 vs. 
DMSO or CFTR KO by two-way ANOVA.  B.  Comparison of the maximal inhibitory effect of 
CFTRinh-172 on WT and CFTR KO cardiomyocyte contraction rate.  ***, P < 0.001 vs. DMSO 
by one-way ANOVA; +++, P < 0.001 vs. 10 µM CFTRinh-172 by student’s t-test. 
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Figure 2.2.  Inhibition of CFTR increases Ca2+i via L-type Ca2+ channels.  A.  Quiescent WT 
ventricular myocytes were loaded with Fura-2 to monitor changes in Ca2+i.  Following a 3-
minute baseline, CFTRinh-172 (20 µM, n = 32) or DMSO (n = 19) was added and subsequent 
effects were measured for 20 minutes.  B. WT cardiomyocytes were bathed in Ca2+-free solution 
(n = 25), pretreated with ryanodine (10 µM) and thapsigargin (1 µM) (n = 26), KB-R7943 (10 
µM, n =  23), nifedipine (10 µM, n = 26), or KB-R7943 and nifedipine (n = 23) for 30 minutes 
prior to Ca2+i measurements.  Additionally, in CFTR KO myocytes, Fura-2 fluorescence was 
monitored upon CFTRinh-172 (20 µM, n = 23) or DMSO (n = 24) addition.  ***, P < 0.001 vs. 
CFTRinh-172 by student’s t-test. 
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Figure 2.3.  CFTRinh-172-induced activation of L-type Ca2+ channels causes inhibition of 
PKA and contraction rate.  A.  Quiescent WT ventricular myocytes were infected with 
AKAR2.2 to monitor real-time changes in PKA activity.  Following a 5-minute baseline, 
CFTRinh-172 (20 µM, n = 24) or DMSO (n = 18) was added and subsequent effects were 
measured for 20 minutes.  B.  WT cardiomyocytes were pretreated with nifedipine (10 µM, n = 
24) for 30 minutes prior to CFTRinh-172 addition.  Additionally, PKA activity following 
CFTRinh-172 (20 µM, n = 19) was monitored in CFTR KO myocytes.  In separate experiments, 
the effect of BayK-8644 (1 µM, n = 15) on PKA activity in WT cardiomyocytes was measured.  
C.  Syncytial WT ventricular myocytes were treated with PKI (20 µM, n = 8) for 30 minutes 
following a 10-minute baseline.  *, P < 0.05; **, P < 0.01 vs. CFTRinh-172; ++, P < 0.01 vs. 
DMSO by student’s t-test. 
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Figure 2.3 continued… 
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Figure 2.4.  CaMKII activity is required to maintain normal contraction rates following 
pharmacological inhibition or genetic deletion of CFTR. A.  Syncytial WT ventricular 
myocytes were treated with H2O (n = 5) or AIP (1 µM, n = 6) for 30 minutes following a 10-
minute baseline.  B.  Separately, the effect of simultaneous addition of AIP plus CFTRinh-172 (20 
µM, n = 8) for 20 minutes was examined and compared to responses by CFTRinh-172 alone 
(from Figure 1A).  *, P < 0.05; ***, P < 0.001 vs. CFTRinh-172 alone by two-way ANOVA.  C.  
WT cardiomyocytes were exposed to CFTRinh-172 for various lengths of time (n = 3-5 each) and 
then harvested to examine PLB-Thr17 phosphorylation.  All results were quantified and 
normalized.  A representative blot is shown.  *, P < 0.05 vs. no treatment by student’s t-test.  D.  
Cardiomyocytes from CFTR KO mice (n = 8) were treated with AIP (1 µM) for 30 minutes 
following baseline measurements.  Contraction rates were compared to those from CFTR KO 
mice in Figure 1A.  *, P < 0.05; **, P < 0.01 vs. CFTR KO alone by two-way ANOVA.  E.  A 
comparison of changes in contraction rate due to AIP in WT and CFTR KO mice.  **, P < 0.01 
vs. WT by student’s t-test. 
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Figure 2.4 continued… 
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Figure 2.4 continued… 
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Figure 2.5.  CaCC play an important role in cardiomyocyte contraction rate following 
CFTR inhibition or KO.  A.  Syncytial WT ventricular myocytes were treated with DMSO (n = 
6) or niflumic acid (100 µM, n = 7) for 30 minutes following a 10-minute baseline.  B.  
Separately, the effect of simultaneous addition of niflumic acid (100 µM) plus CFTRinh-172 (20 
µM, n = 8) for 20 minutes was examined and compared to the effect of CFTRinh-172 alone (from 
Figure 1A),  C.  Ventricular myocytes from CFTR KO mice (n = 8) were treated with niflumic 
acid (100 µM) for 20 minutes after baseline measurements. Contraction rates were compared to 
those from CFTR KO mice in Figure 1A.  *, P < 0.05; **, P < 0.01; ***, P < 0.001 vs. CFTR KO 
alone by two-way ANOVA.  D.  A comparison of changes in contraction rate due to niflumic 
acid in WT and CFTR KO mice.  ***, P < 0.001 vs. WT by student’s t-test. 
 
A 
B 
   
 58 
Figure 2.5 continued… 
C 
D 
 59 
CHAPTER 3: 
MULTI-DRUG RESISTANT PROTEIN 4 IN CARDIAC MYOCYTES: ANOTHER 
PLAYER IN THE REGULATION OF INTRACELLULAR cAMP AND β-ADRENERGIC 
SIGNALING 
 
ABSTRACT 
Spatiotemporal regulation of cAMP in cardiac myocytes is integral to regulating the 
diverse functions downstream of β-adrenergic stimulation.  Phosphodiesterases (PDEs) have 
shown to be important in regulating intracellular cAMP levels during β-adrenergic stimulation.  
Recently, in epithelial and smooth muscle cells, it was found that the multidrug resistant protein 
4 (MRP4) acts as a cAMP efflux pump to regulate intracellular cAMP levels and alter effector 
function.  In the current study we investigated the potential role of MRP4 in regulating 
intracellular cAMP and β-adrenergic stimulated contraction rate in cardiac myocytes.  Cultured 
neonatal ventricular myocytes were used for all experiments.  In addition to wildtype mice, β1-, 
β2-, β1/β2-adrenergic receptor, and cystic fibrosis transmembrane conductance regulator (CFTR) 
knockout mice were used.  MRP4 expression was probed via Western blot, intracellular cAMP 
was measured by fluorescent resonance energy transfer, while the functional role of MRP4 was 
assayed via monitoring of isoproteronol-stimulated contraction rate.  We found that MRP4 is 
expressed in mouse neonatal ventricular myocytes.  A specific pharmacological inhibitor of 
MRP4, MK571, resulted in accumulation of intracellular cAMP and potentiated submaximal 
isoproteronol stimulation via β1-adrenergic receptors.  Additionally, this potentiating effect on 
contraction rate was dependent on CFTR expression.  This was in contrast to PDE4-dependent 
potentiation of contraction rate, which was not CFTR-dependent.  Thus, we have shown, for the 
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first time, a role for MRP4 in the regulation of cAMP and β-adrenergic signaling in cardiac 
myocytes.  Together with PDEs, MRP4 must also be considered when examining cAMP 
regulation in cardiac myocytes. 
 
INTRODUCTION 
The spatial and temporal control of cAMP has become widely accepted as the means 
whereby a single signaling molecule can lead to a diverse array of cellular responses.  This 
concept has been widely studied in cardiac myocytes and recently commented on (1).  Multi-
layer compartmentalization of cAMP signaling occurs as a result of differential localization of β-
adrenergic receptor subtypes, adenylyl cyclase, PKA, Epac, and phosphodiesterases (PDEs) via 
anchoring proteins, such as A-kinase anchoring proteins (2).  The concentration and spread of 
cAMP is considered to be largely controlled by PDEs, which are responsible for terminating the 
signal by breakdown of cAMP.  In cardiac myocytes β-adrenergic-stimulated increases in cAMP 
are predominantly regulated by PDE4 with PDE3 playing a minor role (3-5).  
 Multidrug resistance protein 4 (MRP4) is a member of the ATP-binding cassette (ABC) 
transporters, and was originally described in T-lymphoid cell line as being responsible for efflux 
of antiviral nucleoside-based drugs (6), it has since been found to transport numerous 
endogenous molecules involved in cellular communication and signaling, including, but not 
limited to, organic anions, prostaglandins, conjugated steroids, and cyclic nucleotides (7).  Of 
particular interest, MRP4 has recently been shown to negatively regulate intracellular cAMP 
levels in both epithelial and smooth muscle cells (8, 9).  In colonic epithelial cells, Li et al 
showed that inhibition of MRP4 by MK571 caused a compartmentalized increase in cAMP that 
resulted in activation of the cystic fibrosis transmembrane conductance regulator (CFTR) via 
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PDZK1, which serves as a scaffolding protein for MRP4 and CFTR (8).  In addition to colonic 
epithelial cells, MRP4 is expressed in prostate tubuloacinar cells, hepatocytes, choroids plexus 
epithelium, testis, ovary, adrenal gland, various blood cells, and neurons (7, 10); however, no 
one has examined its presence in cardiac myocytes. 
 
MATERIALS AND METHODS 
Ventricular myocytes were cultured from wildtype (FV/B), β-adrenergic knockout (β1, 
β2, β1/β2 KO), or CFTR KO (strain 2515 B6.129S6-Cftrtm1Kth/J) neonatal mice were used for all 
experiments.  Cells were isolated and cultured using a similar protocol as previously reported 
(11). Cells were plated at high-density for measurement of contraction rate or low-density for 
cAMP measurements.  High-density plating allowed for cells to form a syncytium, whereas low-
density plating facilitated individual quiescent myocytes.  
For expression studies, cultured cardiomyocytes were isolated in 1X dulbecco’s 
phosphate buffer solution containing the protease inhibitors PMSF (250 µM), NaF (2.5 mM), 
Na3VO4 (2.5 mM), benzamidine (1 mM) and lysed in PBS with 2% Triton-X 100 and 
centrifuged prior to protein estimation.  For electorphoresis, samples were run out on a 4-15% 
agarose gel.  Following transfer to a PVDF membrane, MRP4 was detected using an IgG anti-
MRP4 antibody. 
We utilized fluorescent resonance energy transfer (FRET) to measure real-time changes 
in intracellular cAMP.  24 hours after initial culture, isolated cardiomyocytes were infected with 
adenovirus containing the cAMP sensor ICUE3 for 24-48 hours.  Acquisition was set to 200 
millisecond exposure in both channels every 20 seconds. The binding of cAMP to the EPAC site 
 62 
of ICUE3 causes a decrease in FRET (12). Yellow-to-cyan ratios were calculated at different 
time points, background corrected, and normalized. 
Measurement of myoctye contraction rate was performed as previously reported (13).  35 
mm dishes were placed in a temperature/CO2 regulated apparatus.  Using a CCD camera and 
MetaMorph imaging software, 5-second video images were obtained every 2 minutes. 
Movements in the x and y plane were calculated and number of deflections noted as number of 
contractions. 
Isoproterenol came from Sigma-Aldrich (St. Louis, MO).  MK571 was purchased from 
Cayman Chemical (Ann Arbor, MI). Rolipram was from Calbiochem (San Diego, CA).  
CFTRinh-172 was obtained from Calbiochem and the Cystic Fibrosis Foundation Therapeutics 
(Chicago, IL).  Drugs were made as 1:1000 stock solutions and diluted the day of the 
experiment.   
For comparison between two groups of data, student’s t-test was used to determine 
significance, while multiple groups were compared by analysis of variance (ANOVA).  Results 
were considered significant at P < 0.05 and are denoted accordingly. 
 
RESULTS AND DISCUSSION 
 We first examined the expression of MRP4 in mouse neonatal ventricular myocytes.  As 
seen in Figure 3.1A, in two different samples, a specific anti-MRP4 antibody recognized MRP4 
protein.  Subsequently, we examined if MRP4 was functional and if it regulated intracellular 
cAMP, as has been shown in other cell types (8, 9).  We first examined the effect of MK571 (40 
µM), a specific inhibitor of MRP4, on resting intracellular cAMP.  While DMSO had a short-
lived artifactual effect on cAMP measurements, it had no lasting effect on intracellular cAMP.  
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In contrast, MK571 caused a significant and prolonged increase in resting cAMP levels (Figure 
3.1B).  Thus we see that MRP4 is involved in regulating intracellular cAMP levels during resting 
conditions.  While significant increases in resting cAMP can be achieved through broad 
inhibition of PDEs by agents such as IBMX, individual inhibition of PDE3 or PDE4, which 
constitute the major types in the heart, produce zero to minimal effects on resting cAMP (14).  
Therefore, with the substantial elevation of cAMP by MRP4 inhibition, we propose that MRP4 is 
a major regulator of resting cAMP. 
 β-adrenergic receptor activation, and subsequent cAMP generation, is a physiological 
event well-utilized by the body to manipulate cardiac function in response to various stimuli.  
Therefore, we examined the potential role of MRP4 in modulating β-adrenergic stimulated 
cAMP generation.  Similar to previous findings (Soto et al, in preparation), in DMSO-treated 
cells, stimulation with submaximal isoproterenol (10-8 M) resulted in a transient increase in 
cAMP (Figure 3.1C), whereas maximal (10-5 M isoproterenol) stimulation caused a prolonged 
increase in intracellular cAMP (Figure 3.1D).  In contrast, simultaneous addition of MK571 and 
submaximal isoproterenol led to a rapid and prolonged increase in cAMP that was significantly 
different from DMSO and isoproterenol stimulation (P < 0.001) (Figure 3.1C).  Stimulation with 
MK571 and maximal isoproterenol led to a similar response (P > 0.001 vs. DMSO and 
submaximal) and overall was no longer significantly different than stimulation with DMSO and 
maximal isoproterenol; although some initial time points following stimulation were statistically 
increased (P < 0.05).  In the previously mentioned study by Soto et al, they found that PDE4 
inhibition led to similar increases in cAMP as we observed for MRP4 inhibition.  Based on these 
results and others (15), it has been proposed that activation of PDE4 following β-adrenergic 
receptor stimulation is responsible for the transient nature of submaximal stimulation.  While it is 
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tempting to say that MRP4 inhibition is also involved in this process, we did not measure MRP4 
activity during receptor stimulation.  Future studies are necessary to determine if MRP4 activity 
is altered during β-adrenergic receptor stimulation and how this correlates with PDE4 and other 
activated/inhibited factors. 
Subsequently, we examined if alteration of MRP4 activity resulted in a functional effect 
on cardiac myocytes through modulating β-adrenergic stimulated cardiomyocyte contraction 
rate.   Compared to DMSO-treated cells, MK571 significantly increased cardiomyocyte 
contraction rate in response to stimulation by submaximal isoproteronol; whereas at maximal 
concentrations there was no difference between DMSO and MK571-treated cells (Figure 3.2A).  
These findings are in agreement with our findings that MK571 increases intracellular cAMP 
compared to DMSO at submaximal, but not maximal, concentrations of isoproterenol (Figure 
3.1C and 3.1D).  While we did not examine discrete microdomains, ratio images suggest that 
MK571 preferentially increases isoproterenol-stimulated cAMP at the plasma membrane.  
Additionally, we investigated if MRP4 potentiates submaximal isoproteronol-stimulated 
contraction rate in a non-specific manner or if it is receptor subtype specific. To do so we 
examined the effect of MK571 on submaximal isoproteronol stimulated potentiation of 
contraction rate in β1, β2, and β1/β2 KO mice.  We found that MK571 caused a significant 
increase in submaximal isoproteronol stimulated contraction rate compared to control in β2 KO 
mice, but not β1 or β1/β2 KO mice (Figure 3.2B), indicating that MRP4 potentiates isoproteronol-
stimulated contraction rate in a receptor-specific manner involving β1-adrenergic receptors.  
These findings are in contrast to previous work showing that inhibition of PDEs can increase 
contraction rate in both β1 and β2 KO mice (15). 
 65 
 Based on previous findings that MRP4 activity can influence CFTR activity in epithelial 
cells (8), we examined if MRP4-dependent potentiation of contraction rate involved CFTR.  In 
repeating similar experiments above using CFTR KO mice, we found that CFTR was required 
for MK571-dependent potentiation of contraction rate (Figure 3.2C), indicating that CFTR is 
crucial to this process.  To determine if PDE4-dependent potentiation of contraction rate by is 
also CFTR-dependent, we examined the effect of rolipram in CFTR KO mice.  In contrast to our 
findings with MRP4, inhibition of PDE4 does not require CFTR as rolipram continued to 
increase contraction rate in response to submaximal isoproterenol stimulation (Figure 3.1D).  
Thus, while inhibition of both MRP4 and PDE4 increase cAMP and contraction rates during 
submaximal β-adrenergic stimulation, we have shown that they possess different properties in 
how they do so.  MRP4 inhibition has been shown to increase cAMP in a highly localized 
manner (8), whereas it is thought that PDE4 inhibition may lead to increased diffusion of cAMP 
(3).  Our observations that MK571 increased isoproterenol-stimulated cAMP along the plasma 
membrane, coupled with our findings that MRP4-dependent potentiation is CFTR-dependent, 
leads us to propose that in cardiac myocytes inhibition of MRP4 produces a an increase in cAMP 
near the membrane where CFTR is located.  Whether MRP4 and CFTR physically interact in 
cardiac myocytes remains to be seen.  Future experiments investigating the intricacies of how 
MRP4 activity is altered during β-adrenergic stimulation is required, however, we have shown 
for the first time that MRP4 is expressed and functional in cardiac myocytes and potentiates β-
adrenergic stimulated contraction in a manner distinct from PDE4.  Thus, future studies 
examining cAMP regulation in cardiac myocytes should take into consideration the potential 
involvement of MRP4. 
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Figure 3.1.  Expression and function of MRP4 in mouse neonatal ventricular 
cardiomyocytes.  A.  Cardiomyocytes from two different samples (both WT) were cultured and 
harvested in lysis buffer. 200 µg and 40 µg of cardiomyocytes or HEK cells, respectively, were 
loaded into agarose gels. Expression of MRP4 was probed via an anti-MRP4 antibody (1:5000). 
B. WT ventricular myocytes infected with ICUE3 were exposed to DMSO (n ≥ 20) or MK571 
(40 µM, n ≥ 22) for 20 minutes following a 3-minute baseline.  C and D.  In separate 
experiments, following baseline measurements, cardiomyocytes were stimulated with  with 
DMSO + 10-8 M isoproterenol (n = 20) or MK571 (40 µM) + 10-8 M isoproterenol (n = 23) for 
20 minutes.  Similar experiments were also carried out with 10-5 M isoproterenol (DMSO, n = 
21; MK571, n = 25).  Representative ratios of cardiomyocytes are shown in pseudocolor at 
baseline and peak responses for each treatment. 
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Figure 3.1 continued… 
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Figure 3.1 continued… 
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Figure 3.2. Characterization of the effect of MRP4 inhibition on cardiomyocyte contraction 
rate.  A.  Spontaneous beating syncytial WT ventricular myocytes were pre-treated with DMSO 
(n = 5) or MK571 (40 µM, n = 5) for 20 minutes prior to isoproterenol stimulation.  
Cardiomyocytes were stimulated with submaximal isoproterenol (10-8 M), followed by maximal 
isoproterenol (10-5 M), for 20 minutes. B.  Additionally, the effects of MK571 on submaximal 
isoproterenol stimulation was examined in β1 KO, β2 KO, β1/ β2 KO mice (n ≥ 6).  C.  CFTR KO 
mice (n = 6) were exposed to MK571 in a similar manner as Figure 2A.  D.  Additionally, in 
separate experiments, the same types of conditions were tested using rolipram (10 µM; n ≥ 6) 
instead of MK571. ***, P<0.001 vs. β2 KO DMSO by student’s t-test. 
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Figure 3.2 continued… 
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CHAPTER 4: 
IN VITRO AND IN VIVO EXAMINATION OF CFTR IN β-ADRENERGIC 
STIMULATED HEART FUNCTION 
 
ABSTRACT 
 β-adrenergic receptor stimulation triggers a diverse array of intracellular signals that 
affects many ion transporters and channels in an effort to increase cardiac output. With our 
previous findings that CFTR is involved in the regulation of un-stimulated cardiomyocyte 
contraction rate, we set out to determine if CFTR is also involved in β-adrenergic stimulated 
contraction rate.  To do this, we utilized in vitro and in vivo approaches using the neonatal 
cardiomyocyte contraction rate assay and left ventricular catheterization to measure heart rate, 
systolic, and diastolic function.  Post-mortem structural analysis and immunohistochemistry was 
also performed.  In vitro, we found that positive or negative regulation of CFTR activity using 
the CFTR activators genistein and PG-01 or the CFTR inhibitor CFTRinh-172 and CFTR 
knockout myocytes preferentially affect submaximal isoproterenol-stimulated contraction rate in 
a positive or negative manner, respectively.  In vivo, CFTR knockout mice displayed altered 
resting cardiac function parameters with increased heart size, heart rate, contraction, and 
relaxation, while maintaining normal left ventricular end-diastolic pressure.  β-adrenergic 
stimulation with dobutamine produced normal increases in heart rate, contraction, and relaxation,  
however, at the expense of increased left ventricular end-diastolic pressure.  Structural 
disturbances preferentially affected male knockout mice and may correlate with decreased 
Ca2+/calmodulin-dependent kinase II expression in male CFTR knockout mice.  Our findings 
show that CFTR is involved in the modulation of β-adrenergic stimulated heart function and that 
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chronic loss of CFTR leads to cardiac disturbances.  These findings have important implications 
for cystic fibrosis patients and their potential susceptibility to heart disease. 
  
INTRODUCTION 
 Proper inotropic control of the heart is integral to maintaining heart function, as 
illustrated by the loss of inotropy during heart failure and the widespread clinical use of positive 
inotropic agents to combat the ill effects of heart failure.  Tight control of cardiomyocyte 
inotropy occurs predominantly through β-adrenergic receptors and their diverse downstream 
effectors.  Activation of different β-adrenergic receptors (β1 vs. β2 vs. β3) produces distinct 
intracellular signals and functional responses in cardiomyocytes (1).  In particular, β1-adrenergic 
receptor activation has been shown to be the primary mode of increasing cardiac output by 
increasing the contraction rate and contractility of cardiac muscle cells. Simplistically, β1-
receptor activation leads to activation of protein kinase A (PKA) via increased production of 
cAMP by adenylate cyclase.  Subsequently, PKA directly phosphorylates and enhances the 
activity of a host of ion channels and transporters, which have been summarized by Kuzumoto et 
al (2), but include the sarcolemmal L-type Ca2+ current, the slowly activating component of 
delayed rectifier K+ current, the plasma membrane Ca2+-ATPase, the ryanodine receptor (3), and 
phospholemman and phospolamban, which regulate the Na+/K+ ATPase and sarcoplasmic 
reticulum Ca2+ pump (SERCA), respectively (4).  In addition, the cystic fibrosis transmembrane 
conductance regulator (CFTR) anion channel is directly regulated by PKA phosphorylation of its 
regulatory domain, leading to an increase in membrane Cl- conductance.   
Cardiac expression of CFTR has been shown in a variety of species, including rodents 
and humans (5, 6).  Simulation studies by Kuzumoto et al predicted that increases or decreases in 
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CFTR channel density would positively or negatively alter action potential duration, 
respectively, due to β-adrenergic stimulation (2).  However, in electrophysiological studies there 
has been controversy whether CFTR in the heart is activated by β-adrenergic stimulation, with 
Zakharov et al reporting isoprenaline-stimulated CFTR currents (7), and  Levesque et al 
reporting that isoprenaline failed to stimulate CFTR currents (8).  These conflicting reports have 
led to questions regarding the importance of CFTR in the heart.  However, in non-
electrophysiological experiments, CFTR has been shown to be up-regulated during ischemia (9), 
involved in the protection of ischemic preconditioning (10), and down-regulated in patients with 
heart failure (11).  Additionally, we have shown that in neonatal ventricular myocytes CFTR is 
involved in regulating contraction rate during un-stimulated spontaneous beating (Chapter 2).  
 The ongoing question of the importance of CFTR in cardiac physiology has also been 
confounded by the complexity of studying its effects in humans.  In other systems, cystic fibrosis 
(CF) patients, who have defects in CFTR, provide the ideal model in defining the role of CFTR.  
However, these patients typically present with significant lung disease, which can indirectly lead 
to alterations in left ventricular function through right ventricular defects.  Thus, studies that 
have reported left ventricular defects in CF patients are confounded by a clear understanding of 
whether these CFTR defects in the heart lead to primary disruptions in cardiac function or are 
secondary to lung function abnormalities.  To address these issues and understand if CFTR is 
physiologically involved in β-adrenergic stimulation heart function we undertook a series of in 
vitro and in vivo experiments utilizing acute pharmacological inhibition of CFTR and chronic 
deletion of CFTR with CFTR KO mice.  These methods allowed us to examine potential primary 
defects in cardiac myocytes and since CFTR KO mice do not develop lung disease, we can study 
heart function in vivo without the complications of lung pathology.  In vitro, we found that loss 
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of CFTR leads to primary defects in β-adrenergic stimulated cardiomyocyte contraction.  CFTR 
KO mice showed altered dependence on other ion channels, such as Ca2+-activated Cl- channels, 
which allows for compensation under some, but not all, circumstances.  In vivo, we found heart 
function abnormalities under un-stimulated and stimulated conditions.  Additionally, post-
mortem analysis of CFTR KO hearts, revealed structural changes and alterations in CaMKII 
expression.  These findings may have implications for CF patients in understanding their risks 
for heart disease. 
 
MATERIALS AND METHODS 
Ethical approval of animal use.  FV/B mice were obtained from Charles River 
Laboratory (Wilmington, MA) and used for generation of wildtype (WT) mice.  CFTR KO mice 
(strain 2515 B6.129S6-Cftrtm1Kth/J) were initially obtained from Dr. Deborah Nelson at the 
University of Chicago (Chicago, IL) and bred in-house.  Neonatal mice were were used within 
24 hours of birth while adult animals were 2-4 months old.  Use of animals was approved by the 
University of Illinois at Urbana-Champaign IACUC. 
Isolation and culture of neonatal and adult mouse cardiomyocytes. Ventricular 
myocytes were cultured from neonatal and adult mice for using a similar protocols as previously 
reported (12).  For neonatal cardiomyocytes, freshly born mice were sacrificed by decapitation 
with surgical scissors.  Cardiac tissue devoid of atria were exposed to enzymatic digestion.  
Subsequently, isolated cells were pipetted onto 35 mm Petri dishes pre-coated with 1.5% gelatin 
type A and plated at high-density to facilitate formation of a syncytium of spontaneously beating 
myocytes.  Cells were cultured fro 2-3 days and culture media (containing serum and 20 mM 
HEPES for buffering) was replaced daily and at least 1 hour prior to experiments. 
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Measurement of contraction rate in vitro.  Measurement of neonatal myoctye 
contraction rate was performed as previously reported (13).   35 mm dishes were placed in a 
temperature/CO2 regulated apparatus.  Using a CCD camera and MetaMorph imaging software, 
5-second video images were obtained every 2 minutes.  Following acquisition, a specific point 
within the field was selected and analyzed for movement in each x, y, and z plane.  Movements 
in the x and y plane were calculated and number of deflections noted as number of contractions. 
Each data point represents a single observation from different experiments so that only one data 
set was obtained from each experiment.  Each drug was tested using multiple isolations to ensure 
that the observed responses were not particular to a single isolation. 
 Measurement of heart function in vivo.  The protocol for in vivo hemodynamic studies 
in the mouse was derived from the description by Rockman et al (14) and carried out by the 
Mouse Cardiovascular Phenotyping Core Facility at Washington University, St. Louis. Adult 
mice were anesthetized with thiopental sodium (60 mg/kg, intraperitoneally).  This anesthesia 
produces a normal heart rate of 500 beats/min while still allowing for a surgical plane of 
anesthesia. The mice are then intubated and ventilated with a Harvard ventilator set at 200-400 
µL. The bilateral carotid arteries were identified in the region of the trachea and cannulated with 
a 1.4 french high fidelity micromonometer catheter from Millar Instruments, which was then 
inserted into the cartotid artery, advanced across the aortic valve, and secured in the left 
ventricle. Hemodynamic measurements were recorded at baseline and 60 seconds after injection 
of bolus doses of dobutamine. Continuous left ventricular (LV) systolic and diastolic pressures, 
and the derivatives of left ventricular pressure (dP/dt) were recorded on a laptop commuter with 
Millar analysis software.  After successful recording of functional data, mice were euthanized by 
anesthetizing with thiopental sodium followed by cervical dislocation. 
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 Histology.  Brains, spleens, and hearts were promptly removed from euthanized adult 
mice and placed in cassettes in 10% formalin for 24 hours.  Susbseqently, tissues were dried in 
70% ethanol and shipped to the Histology Core Facility at the University of California, San 
Diego.  There tissues were paraffin embedded, sectioned, and processed for hematoxylin and 
eosin (H&E), TUNEL, trichrome, periodic acid-schiff  (PAS), and immunohistochemistry with 
antigen retrieval using established protocols.  Ca2+/calmodulin-dependent kinase II (CaMKII) 
was detected using a polyclonal rabbit anti-CaMKII antibody from Santa Cruz Biotechnology 
(H300).  Spleens were used as controls for proliferation and brains as controls for CaMKII 
expression.  Tissues were coded so that their identities were blinded to the technicians and 
histopathologist (Dr. Nissi Varki, UCSD) working with and analyzing samples.  Additionally, 
using H&E sections, the areas of left and right ventricles and interventricular septum were 
measured using ImageJ software. 
 Chemicals.  Isoproterenol and genistein were purchased from Sigma-Aldrich (St. Louis, 
Missouri), CFTRinh-172 and PG-01 was obtained from Cystic Fibrosis Foundation Therapeutics 
(Chicago, IL).  CFTRinh-172 was also purchased from Calbiochem (San Diego, CA).  The Mouse 
Cardiovascular Phenotyping Core Facility at Washington University, St. Louis, independently 
acquired dobutamine. 
 Statistics.  All data are expressed as means ± SEM, except where indicated.  Student’s t-
test was used for comparison of two groups, two-way ANOVA was used to compare time 
courses and one-way ANOVA was used to compare multiple groups.  Statistics were performed 
by GraphPad Prism software, while EC50s were calculated using SigmaPlot. 
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RESULTS 
 Measurement of in vitro cardiomyocyte contraction rate.  To determine if CFTR has 
an intrinsic role in β-adrenergic stimulated heart function, we examined the effect of acute and 
chronic CFTR loss on isoproterenol-stimulated contraction rate.  In WT cardiomyocytes 
isoproterenol dose-dependently increased cardiomyocyte contraction rate (Figure 4.1).  In 
contrast, in WT myocytes pretreated with the selective CFTR inhibitor, CFTRinh-172 (20 µM), or 
CFTR KO mice, isoproterenol failed to stimulate any increase in contraction rate at submaximal 
concentrations (Figures 4.1.A-C).  Specifically, while 10-8 M isoproterenol stimulated a 
significant increase in contraction rate in control myocytes, this same concentration produced no 
response in CFTRinh-172-treated myocytes or those from CFTR KO mice.  Despite these defects, 
CFTR loss had no deleterious impact on concentrations of isoproterenol that stimulated maximal 
increases in contraction rate (10-7 M to 10-5 M).  To further understand the impact of CFTR 
activity on contraction rate, we performed similar experiments with myocytes pretreated with 
genistein and PG-01, which have been shown to directly activate CFTR (15, 16).  In a similar 
manner as CFTR loss, increasing the activity of CFTR preferentially affected contraction rates at 
submaximal isoproterenol stimulation (10-8 M), with no effect on maximal stimulation (10-5 M) 
(Figure 4.1.C).  Thus, modulation of CFTR activity appears to preferentially modulate 
submaximal isoproterenol stimulated contraction rate, with gain of CFTR activity leading to a 
right-shift and loss of CFTR activity a left-shift of the isoproterenol-stimulated contraction rate 
dose response curve (Table 4.1). 
 In lung and intestinal epithelial cells CFTR has been shown to associate with β2-
adrenergic receptors (17, 18).  Therefore, we sought to determine if CFTR-dependent depression 
of contraction rate involves β2-adrenergic receptors.  Utilizing β-adrenergic receptor KO mice, 
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we found isoproterenol stimulated contraction rate increases at both submaximal (10-8 M) and 
maximal (10-5 M) doses (Figure 4.2A) in a manner that was dependent on β1-adrenergic 
receptors.  Subsequently, using β2 KO mice, we repeated previous experiments examining the 
effect of CFTR inhibition on submaximal and maximal stimulated contraction rate using 
CFTRinh-172.  In β2 KO mice, CFTRinh-172 (20 µM) continued to preferentially inhibit 
submaximal isoproterenol (10-8 M) stimulated contraction rate, with no effect at maximal 
stimulation (10-5 M) (Figure 4.2B).  Thus, in cardiac myocytes CFTR appears to modulate β1-
adrenergic receptor stimulation to control increases in contraction rate. 
 In an effort to understand why CFTR is particularly critical for submaximal β-adrenergic 
stimulated contraction rate we examined the effect of PDE4 and MRP4 inhibition, which have 
been shown to modulate intracellular cAMP levels in cardiac myocytes (19)(Chapter 3), on 
contraction rate during CFTR loss.  In cardiomyocytes with functional CFTR (control), 
inhibition of PDE4 or MRP4 by rolipram (10 µM) or MK571 (40 µM), respectively, led to a 
significant increase in submaximal isoproterenol (10-8 M) stimulated contraction rate (Figure 
4.3).  In WT myocytes pretreated with CFTRinh-172 or myocytes from CFTR KO mice, rolipram 
continued to cause an increase in isoproterenol-stimulated contraction rate, although the 
magnitude between acute and chronic loss of CFTR differed (P < 0.001).  In contrast, MK571 
failed to stimulate any increase submaximal isoproterenol stimulated contraction rate in CFTRinh-
172 treated or CFTR KO cardiomyocytes.  Thus, it appears that while CFTR is critical for 
submaximal stimulated increases in contraction rate under normal circumstances, this defect can 
be overcome by inhibition of PDE4, but not by MRP4. 
 Subsequently, we sought to determine if the normal increases in maximal stimulated 
contraction rate were a result of CFTR not being involved in the response to maximal stimulation 
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or if acute or chronic loss of CFTR led to altered regulation of Ca2+/calmodulin-dependent kinase 
II (CaMKII) and/or Ca2+-activated Cl- channels, as we have shown previously for baseline 
contraction (Chapter 2).  To probe this we examined the effect of myristoylated-autocamtide-2-
inhibitory peptide (AIP; 1 µM) or niflumic acid (100 µM) on maximal (10-5 M) isoproterenol-
stimulated contraction rates in WT myocytes with and without CFTR inhibition and in CFTR 
KO mice.  As seen in Figure 4.4A, inhibition of CaMKII by AIP caused a significant elevation in 
isoproterenol-stimulated contraction rate.  In contrast, when WT myocytes were pretreated with 
AIP and CFTRinh-172, isoproterenol (10-5 M) failed to potentiate contraction rate, but continued 
to increase contraction rate similar to control myocytes (Figures 4.4B-C).  However, in the case 
of CFTR KO cardiomyocytes treated with AIP, isoproterenol potentiated contraction rate in a 
similar manner as AIP in WT myocytes (Figures 4.4B-C).  Subsequently, we examined the effect 
of niflumic acid.    In WT mice, we found that niflumic acid significantly attenuated 
isoproterenol-stimulated contraction rate, with more pronounce effects over time (Figures 4.5A, 
C), indicating that Ca2+-activated Cl- channels are important in contraction rate responses to 
maximal isoproterenol stimulation.     When we examined how these responses were affected by 
acute and chronic loss of CFTR activity, we found that treatment of WT myocytes with niflumic 
acid and CFTRinh-172 significantly inhibited any increase in isoproterenol-stimulated contraction 
rate (Figures 4.5B-C).  In contrast, niflumic acid treatment in CFTR KO mice produced similar 
responses as niflumic acid treatment in WT mice (Figure 4.5B).  Thus, we have shown that 
during acute, but not chronic, CFTR loss, Ca2+-activated Cl- channels appear to play an increased 
role in contraction rate increases due to maximal isoproterenol stimulation.   
 Measurement of in vivo heart function.  Subsequently, to determine if loss of CFTR 
leads to in vivo cardiac disturbances, we measured in vivo left ventricular function in WT and 
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CFTR KO mice.  Since CFTR KO mice do not display lung abnormalities, it is an ideal model 
for studying heart function independent of lung dysfunction.   Through catheterization of the left 
ventricle we obtained measurements for heart rate, indices of contraction (+dP/dt) and relaxation 
(-dP/dt), and left ventricular end-diastolic pressure (LVEDP).  As seen in Figure 4.6, in 
comparison to WT mice, CFTR KO mice display altered heart function at rest.  We found that 
CFTR KO mice had significantly elevated heart rate, +dP/dt, and -dP/dt at rest, indicating that 
heart activity is increased in these mice (Figure 4.6A-C).  While activity was increased, there did 
not appear to be any dysfunction as resting LVEDP in CFTR KO mice was normal compared to 
WT mice (Figure 4.6D).  Following resting measurements, we perfused increasing 
concentrations of the inotropic agent dobutamine, which serves as a β-adrenergic agonist in vivo 
(20), and measured subsequent changes in heart function.  In contrast to resting measurements, 
dobutamine stimulated similar increases in heart rate, +dP/dt, and  -dP/dt compared to WT mice, 
however, CFTR KO mice developed significantly elevated LVEDP during stimulation (Figure 
4.7).  Thus, while CFTR KO mice are able to properly respond to stimulatory conditions, this 
comes at the cost of increased dysfunction as indicated by changes in LVEDP.  Post-mortem 
analysis of heart sizes revealed a trend in an increased size of hearts from CFTR KO mice 
compared to WT mice (Figure 4.8A), further indicative of heart abnormalities in CFTR KO 
mice. 
 Characterization of heart structure.  In addition to functional studies, in separate 
animals, we performed an in depth analysis of the structure of the hearts from WT and CFTR KO 
mice to determine if any abnormalities existed.  H&E, PAS, Trichrome, and TUNEL assays 
revealed no significant differences between WT and CFTR KO mice, indicating no structural 
damage or elevated apoptosis in CFTR KO hearts.  Despite these findings, measurement of left 
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ventricular (LV), right ventricular (RV), and interventricular septal sizes showed that CFTR KO 
mice have significantly elevated left ventricular and interventricular septal (IVS) areas (Figure 
4.8B-C).  Right ventricular size was comparable between WT and CFTR KO mice.  Thus, this 
data indicates that CFTR KO mice, which have normal lung function (and corresponding normal 
right ventricle size), have elevated heart size due to increased left ventricular and interventricular 
septal areas. 
CaMKII expression.  Based on our findings that CaMKII inhibition can affect 
contraction rates (Figure 4.4, Chapter 2) and is involved in cardiac hypertrophy (21), we 
examined if CaMKII expression is altered in the hearts of CFTR KO mice.   
Immunohistochemical analysis showed that in 3 of 5 samples there was decreased CaMKII 
expression in CFTR KO mice, compared to WT mice (Figure 4.9).  When we examined the 
origin of these tissues, we noticed that the tissues that showed decreased CaMKII expression 
were exclusively from male CFTR KO mice.  When we partitioned the samples by gender we 
found that in all heart tissues from males CaMKII expression was decreased, whereas in female 
heart tissues there was no noticeable changes between WT and CFTR KO mice (Figure 4.9).  
Thus, it appears that chronic loss of CFTR leads to a down-regulation of CaMKII, however, this 
appears to be gender-specific, only occurring in males. 
 Potential gender differences.  Based on our findings with CaMKII expression, we re-
examined our heart structure data to determine if there were differences in male vs. female 
hearts.  As seen in Table 4.2, separation of data by sexes shows that cardiac structural cardiac 
defects appear to predominantly affect male CFTR KO mice.  Compared to WT mice, there was 
no difference between whole heart, left ventricle, or interventricular sizes in female CFTR KO 
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mice.  In contrast, the significance of these parameters in male CFTR KO mice was enhanced 
(see bolded boxes). 
 
DISCUSSION  
 In the current study we provide the first experimental evidence that loss of CFTR causes 
primary defects in β-adrenergic stimulated heart function.  In isolated cardiomyocytes we found 
that CFTR is critical for producing increases in submaximal β-adrenergic stimulated contraction 
rate.  Interestingly, this defect could be overcome by inhibition of PDE4, but not MRP4.  While 
both PDE4 and MRP4 negatively regulate intracellular cAMP (19, Chapter 3), PDE4 inhibition 
causes an increase in cytosolic cAMP, while MRP4 inhibition increases cAMP in a localized 
manner near the membrane (22)(Chapter 3).  Thus, we propose that CFTR is responsible for 
responding to local changes in cAMP due to submaximal isoproterenol stimulation. 
While CFTR loss alone does not alter responses to maximal β-adrenergic stimulation, 
this does not discount its involvement.  When we inhibited both CFTR and Ca2+-activated Cl- 
channels we found that myocytes could no longer produce an increase in contraction rate, which 
was significantly different from Ca2+-activated Cl- channel inhibition alone.  However, in CFTR 
KO mice niflumic acid produced the same response as in WT mice, indicating that other 
channels/transporters likely compensate during chronic CFTR loss.  This may be explained by an 
up-regulation of repolarizing K+ currents in CFTR KO mice, which would compensate for 
outward-conducting Cl- current loss.  Previously, Li et al found that chronic CaMKII inhibition 
led to an upregulation of the fast transient outward current and inward rectifier current (23).  Our 
findings that CFTR KO mice show decreased expression of CaMKII provide a compelling 
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argument for future examination of the expression and activities of these K+ channels in CFTR 
KO mice. 
When we examined β-adrenergic stimulated heart function in vivo we did not find 
contraction defects at submaximal concentrations, as one might expect from our in vitro results.  
We cannot say whether this is due to a differential importance of CFTR in neonatal vs. adult 
myocytes or the increased activity of CFTR KO hearts during non-stimulated conditions.  Since 
we did not measure circulating catecholamine levels in our mice, we cannot rule out a potential 
difference in underlying β-adrenergic stimulation.  However, in our study we found that 
inhibition of CaMKII by AIP led to a significant increase in isoproterenol-stimulated contraction 
rates.  If these results translate to adult mice, decreased expression of CaMKII in CFTR KO mice 
may be responsible for the increased heart activity we observed.  Zhang et al found that chronic 
CaMKII inhibition led to an increase in Ca2+ transients, increased Ca2+i, decreased sarcoplasmic 
reticulum Ca2+, and a trend in increased cardiomyocyte shortening (24); all of which could cause 
an increase in heart activity.  Further examination of these properties in isolated CFTR KO 
cardiomyocytes will clarify whether the increased activity of CFTR KO hearts is due to direct 
alterations in cardiomyocyte properties or secondary to other factors.  
Despite achieving normal β-adrenergic-stimulated increases in heart rate, contraction, 
and relaxation, CFTR KO mice developed an increase in LVEDP.  With the absence of 
contraction/relaxation deficits, we hypothesize that this may be the result of increased afterload 
due to increased aortic constriction in CFTR KO mice (25).  In future experiments, simultaneous 
examination of left ventricular function and aortic constriction will allow us to determine 
whether the increase in LVEDP in CFTR KO mice is due to cardiac or vascular defects.  
Regardless of the origin, defects in LVEDP due to CFTR loss are a significant concern as 
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increased LVEDP is a precursor to the development of heart disease.  In fact, while hearts from 
CFTR KO mice did not show any signs of active apoptosis or inflammation, we did find 
structural alterations compared to WT mice.  CFTR KO mice showed a trend in increased heart 
size compared to WT mice.  When we microscopically examined the heart, right ventricular size 
was normal, as one would expect since these mice do not develop lung disease like CF patients.  
However, the interventricular septum and left ventricles of CFTR KO mice were enlarged, 
indicative of left ventricular hypertrophy. While CaMKII expression is positively associated with 
structural heart disease (21), hypertrophy can occur independent of CaMKII expression (26).  
Rather, this may be the result of chronic overstimulation of CFTR KO hearts or chronic aortic 
hyperconstriction.  Future examination of the cause of this hypertophy is important in 
understanding how chronic CFTR loss affects the heart.  Additionally, it is important to 
determine if CFTR KO hearts progress from hypertrophy (concentric hypertrophy) to atrophy 
and dilation (eccentric hypertrophy).  Our current results suggest that decreased expression of 
CaMKII in CFTR KO mice may prevent the transition from concentric hypertrophy to eccentric 
hypertrophy (26), however, with increased heart activity and aortic constriction in CFTR KO 
mice, they may be at risk for heart failure through arrhythmogenesis and/or pressure overload.  
Interestingly, we found that the structural changes occurring in CFTR KO mice 
predominantly affected male mice.  Estrogens have been shown to activate CFTR (27, 28); 
however, it is unknown whether testosterone has any effect on CFTR activity.  Since sex steroids 
differentially affect both heart function and cardiac disease progression (29), it will be necessary 
to decipher how testosterone and estrogens affect CFTR KO cardiovascular function.  These 
findings may have direct impacts on gender-specific therapies for CF patients.   
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In summary, while further studies are required to clarify the effect of CFTR loss on 
cardiomyocytes and heart function, we have clearly shown that CFTR is involved in regulating 
heart function during β-adrenergic stimulation.  These results, coupled with our previous results 
(Chapter 2) provide evidence that CFTR is involved in modulating both stimulated and un-
stimulated cardiomyocyte contraction.  While CFTR KO mice display “normal” cardiomyocyte 
contraction, this occurs at the expense of altered regulation of other ion channels, signaling 
mediators, stimulated heart function, and changes in heart structure.  Thus, these results, in the 
context of all of our data, provide compelling evidence for the need to carefully investigate the 
heart structure and function of cystic fibrosis patients in order to determine their susceptibility to 
heart disease.  Doing so may lead to an increase in both the quality and quantity of life 
experience by these patients. 
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1.  Modulation of CFTR activity preferentially alters submaximal β-adrenergic 
stimulated contraction rate.  A.  WT (n = 7), WT pretreated with CFTRinh-172 (20 µM, 30 
minutes, n = 4), or CFTR KO (n = 6) neonatal ventricular myocytes were treated with increasing 
doses of isoproterenol (10-11 M to 10-5 M) for 10 minutes each following an initial 10-minute 
baseline.  Values represent responses subtracted from average baseline values.  *, P < 0.05; **, P 
< 0.01 vs. CFTRinh-172 by two-way ANOVA.  ++, P < 0.01; +++, P < 0.001 vs. CFTR KO by 
two-way ANOVA.  B.  Responses from 4.1.A. were normalized and plotted.  C.  In separate 
experiments, CFTR KO (n = 4) or WT neonatal cardiomyocytes were pretreated with DMSO 
(control, n = 6), CFTRinh-172 (20 µM, n = 5), genistein (50 µM, n = 6), or PG-01 (5 µM, n = 4) 
for 20 minutes prior to stimulation with submaximal (10-8 M) or maximal (10-5 M) doses of 
isoproterenol for 20 minutes each. Values represent maximum responses subtracted from average 
baseline values. 
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Figure 4.1 continued… 
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Table 4.1. CFTR modulation alters the dose-dependency of isoproterenol-stimulated 
contraction rate.  Similar to Figure 4.1., neonatal cardiomyocytes were subjected to increasing 
doses of isoproterenol from 10-11 M to 10-5 M (n ≥ 4) and responses were fitted to a standard four 
parameter dose response curve with calculation of half-maximal responses using SigmaPlot. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 EC50 (nM) 
Control 13.8 
CFTRinh-172 33.3 
CFTR KO 38.5 
Genistein 1.2 
PG-01 1.5 
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Figure 4.2.  CFTR-dependent inhibition of β-adrenergic stimulated contraction rate is β2-
receptor independent.  A.  Neonatal ventricular myocytes from β1 (n = 6), β2 (n = 6), and β1/β2 
KO (n = 6) mice were stimulated with submaximal (10-8 M) and maximal   (10-5 M) doses of 
isoproterenol for 20 minutes each following a 10-minute baseline. Peak responses were 
subtracted from averaged baseline values.  *, P < 0.05; ***, P < 0.001 vs. β1 and β1/2 KO by one-
way ANOVA.  ++, P < 0.01 vs. β2 KO 10-8 M.  B.  In separate experiments, cardiomyocytes 
from β2 KO mice were pretreated with DMSO (control, n = 6) or CFTRinh-172 (20 µM, n = 6) 
for 30 minutes prior to stimulation with submaximal (10-8 M) and maximal (10-5 M) doses of 
isoproterenol for 20 minutes each.  *, P < 0.05 vs. control by student’s t-test. 
 
 
A 
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Figure 4.3.  Lack of response to submaximal β-adrenergic stimulation from loss of CFTR 
activity can be overcome by PDE4, but not MRP4, inhibition.  Neonatal cardiomyocytes from 
WT mice with and without CFTRinh-172 pretreatment (20 µM for 30 minutes) or CFTR KO mice 
were treated with rolipram (10 µM, n ≥ 6) or MK571 (40 µM, n ≥ 6) for 20 minutes prior to 
submaximal isoproterenol stimulation (10-8 M) for 20 minutes. *, P <0.05; **, P <0.01; ***, P < 
0.001 vs. 10-8 M alone by student’s t-test. 
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Figure 4.4.  Effect of CaMKII inhibition on maximal β-adrenergic stimulated contraction 
rate during pharmacoligic inhibition or genetic deletion of CFTR.  Neonatal ventricular 
myocytes were treated with AIP (1 µM) for 30 minutes.  Subsequently, cardiomyocytes from 
WT mice (n = 6), WT myocytes pretreated with CFTRinh-172 (20 µM for 20 minutes, n = 8), or 
myocytes from CFTR KO mice (n = 6) were stimulated with 10-5 M isoproterenol for 30 
minutes.  A and B.  Each isoproterenol-stimulated time point was subtracted from baseline 
values preceding stimulation.  *, P < 0.05; **, P < 0.01; ***, P < 0.001 vs. 10-5 M isoproterenol 
alone (A).  ***, P < 0.001 vs. 10-5 M isoproterenol plus AIP (B).  C.  Peak increase in 
isoproterenol-stimulated contraction rate was subtracted from baseline values preceding 
stimulation.  *, P < 0.05; ***, P < 0.001 vs. control (10-5 M isoproterenol).  +++, P < 0.001 vs. 
AIP (plus 10-5 M isoproterenol). 
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Figure 4.4 continued… 
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Figure 4.5.  Effect of Ca2+-activated Cl- channel inhibition on maximal β-adrenergic 
stimulated contraction rate during pharmacoligic inhibition or genetic deletion of CFTR.  
Neonatal ventricular myocytes were treated with niflumic acid (100 µM) for 30 minutes.  
Subsequently, cardiomyocytes from WT mice (n = 7), WT myocytes pretreated with CFTRinh-
172 (20 µM for 20 minutes, n = 7), or myocytes from CFTR KO mice (n = 8) were stimulated 
with 10-5 M isoproterenol for 30 minutes.  A and B.  Each isoproterenol-stimulated time point 
was subtracted from baseline values preceding stimulation.  *, P < 0.05; ***, P < 0.001 vs. 10-5 
M alone (A).  **, P < 0.01 vs. 10-5 M plus niflumic acid (B).  C.  Peak increase in isoproterenol-
stimulated contraction rate was subtracted from baseline values preceding stimulation.  *, P < 
0.05; **, P < 0.01; ***, P < 0.001 vs. control (10-5 M isoproterenol).  ++, P < 0.01; +++, P < 
0.001 vs. niflumic acid (plus 10-5 M isoproterenol). 
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Figure 4.5 continued… 
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Figure 4.6.  In vivo heart function of CFTR KO mice at rest.  Prior to dobutamine 
stimulation, measurements of heart rate (A), maximal systolic pressure (+dP/dt, B), minimum 
diastolic pressure (-dP/dt, C), and left ventricular (LV) end-diastolic pressure (D) were obtained 
from WT (n = 4) and CFTR KO (n = 5) mice.  Responses between WT and CFTR KO mice were 
compared by student’s t-test.  Circles represent data from individual mice and bars represent 
means. 
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Figure 4.6 continued… 
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Figure 4.7.  In vivo β-adrenergic stimulation reveals abnormalities in left-ventricular end-
diastolic pressure in CFTR KO mice.  Increasing doses of dobutamine were administered and 
subsequent responses were compared to baseline values and expressed as percent change from 
baseline. Circles represent data from individual mice and lines represent means. Responses 
between WT (n = 4) and CFTR KO (n = 5) mice at each concentration were compared by 
student’s t-test. 
A 
B 
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Figure 4.7 continued… 
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Figure 4.8.  Cardiac structural disturbances in CFTR KO mice.  A.  Following functional 
studies hearts were weighed  (µg) and compared to body weights (mg).  B.  In separate 
experiments, hearts were fixed, sectioned, and H&E stained.  Areas of left ventricle, right 
ventricle, and interventricular septum were calculated (arbitrary units, a.u.) and normalized to 
body weight (mg).  C.  Representative images from WT and CFTR KO hearts. 
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Figure 4.8 continued… 
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Figure 4.9.  Genetic loss of CFTR leads to decreased expression of CaMKII in male, but not 
female, CFTR KO mice.  Hearts from WT and CFTR KO mice were fixed, sectioned, and 
probed for CaMKII expression using a rabbit polyclonal anti-CaMKII antibody.  Each image 
represents a different heart with the number of animals examined for each gender indicated in 
parenthesis. 
 
 
Male (3) 
 
Female (2) 
 
Female (2) 
 
Male (3) 
  
 
 
WT
CFTR KO
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WT LV Area 
(a.u./mg) 
IVS Area 
(a.u./mg) 
RV Area 
(a.u./mg) 
n Heart/Body 
(µg/mg) 
n 
All 1657 ± 144 
 
1538 ± 125 678 ± 74 5 3.64 ± 0.15 5 
Male 1448 ± 72 
 
1417 ± 51 628 ± 119 3 3.64 ± 0.19 4 
Female 1972 
[1808-2135] 
1720 
[1415-2025]
754 
[697-811] 
2 3.64 1 
CFTR KO 
 
      
All 2333 ± 40 
(0.002) 
2234 ± 92 
(0.002) 
866 ± 64 
(0.09) 
5 4.01 ± 0.13 
(0.09) 
5 
Male 2383 ± 40 
(0.0003) 
2233 ± 59 
(0.0005) 
844 ± 87 
(0.21) 
3 4.13 ± 0.07 
(0.05) 
4 
Female 2257 
[2228-2286] 
(0.23) 
2236 
[1963-2509] 
(0.33) 
899 
[772-1025] 
(0.41) 
2 3.54 
(n/a) 
1 
 
 
 
 
 
Table 4.2.  Cardiac structural abnormalities of CFTR KO mice preferentially occur in 
male mice.  Post-mortem structural analysis of WT and CFTR KO mouse hearts were separated 
according to gender and analyzed similar to Figure 4.8.  Numbers in brackets indicate range of 
values for n < 3.  Numbers in parenthesis indicate P values of CFTR KO vs. WT by student’s t-
test. 
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APPENDIX:  
ADDITIONAL CHARACTERIZATION OF CARDIOMYOCYTE CONTRACTION 
RATE AND THE ION CHANNELS/TRANSPORTERS INVOLVED IN ITS 
REGULATION 
 
EFFECT OF NON-SELECTIVE CFTR INHIBITORS ON CARDIOMYOCYTE 
CONTRACTION RATE 
 Prior to the availability of the selective CFTR inhibitor, CFTRinh-172, we examined the 
effect of commonly used non-selective inhibitors of CFTR on cardiomyocyte contraction rate.  In 
experiments similar to those presented in Chapter 2, syncytial neonatal ventricular myocytes 
were exposed to glibenclamide (100 µM, n = 7) or diphenylamine-2-carboxylate (DPC, 500 µM, 
n = 7).  Both glibenclamide and DPC caused a rapid, significant decrease in cardiomyocyte 
contraction rate that recovered to near-baseline levels (Figure A.1).  Beyond their wide use as 
inhibitors of CFTR, the consistency of responses between glibenclamide and DPC gave us 
confidence that our observed responses were in fact due to inhibition of CFTR and not alternate 
effects as their respective side targets differ from one another (glibenclamide, ATP-dependent K+ 
(KATP) channels; DPC, other Cl- channels).  However, with the importance of KATP channels in 
the heart (1), we examined the effect of 5-hydroxydecanoic acid (5-HD) on contraction rate.  
Inhibition of KATP channels by 5-HD (100 µM) led to no significant alterations in baseline 
contraction rate compared to control (H2O) (18.9 ± 2.7 vs. 11.3 ± 3.2, n = 5 each, P > 0.05 by 
student’s t-test), thereby indicating that the effects observed with glibenclamide inhibition were 
due to inhibition of CFTR, not KATP channels.  Although we discontinued the use of 
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glibenclamide and DPC upon availability of CFTRinh-172, these data provide further evidence 
for the role of CFTR in contraction rate regulation. 
 
ROLE OF HYPERPOLARIZATION-ACTIVATED ‘FUNNY’ CHANNELS IN 
CARDIOMYOCYTE CONTRACTION RATE 
Upon determining that CFTR plays a modulatory role in neonatal ventricular myocyte 
contraction rate, we wanted to understand what is responsible for driving the spontaneous 
beating of cultured neonatal cardiomyocytes.  Similar to sinoatrial nodal cells, ‘funny’ channels 
(If) have been shown to be responsible for spontaneous beating of ventricular myocytes from rats 
(2), therefore we wanted to determine if If is also important in neonatal cardiomyocytes from 
mice.  To determine this, we used the selective If inhibitor, ZD7288, at various doses (1-100 µM) 
and monitored their effects on contraction rate.  As shown in Figure A.2, inhibition of If was 
highly dose-dependent, with full inhibition of contraction rate at higher concentrations.  
Therefore, it appears that similar to rat cardiomyocytes, If is an integral player in driving the 
spontaneous beating of neonatal mouse ventricular myocytes.  This information, together with 
our findings in Chapter 2, provides further evidence for the characterization of spontaneous 
beating cultured neonatal cardiomyocytes. 
 
ROLE OF HCO3- AND EXTERNAL ATP IN CARDIOMYOCYTE CONTRACTION 
RATE 
While widely regarded as Cl- channels, the ability (and importance) of HCO3- to permeate 
CFTR is well documented and accepted.  Therefore, following our observations that CFTR is 
important in contraction rate, we sought to determine the effects of HCO3- removal on 
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cardiomyocyte contraction rate.  To determine the effect of extracellular HCO3- removal on 
baseline and isoproterenol-stimulated contraction rate, experiments were conducted in a similar 
manner as those previously, except in HCO3-/ CO2-free media.  As seen in Figure A.3, removal 
of extracellular HCO3- did not have any inhibitory effect on baseline or isoproterenol-stimulated 
contraction rate.  Furthermore, to eliminate any intracellular sources of HCO3-, we repeated the 
above experiments in the presence of acetazolamide (10-4 mol/L in HCO3-/CO2-free media), a 
broad-spectrum inhibitor of carbonic anhydrase.  Removal of both extracellular and intracellular 
HCO3- resulted in no alteration of baseline or isoproterenol-stimulated contraction rate compared 
to control media (Figure A.3), thereby indicating that HCO3- transport is not necessary for 
contraction rate.  These data suggest that the deleterious effects of CFTR inhibition are likely the 
result of Cl-, not HCO3-, transport. 
In addition to Cl- and HCO3-, CFTR has also been shown to conduct ATP (3), although 
its physiological significance has been questioned.  To determine if the effects of CFTR 
inhibition on cardiomyocyte contraction rate were due, at least in part, to permeation of ATP 
through CFTR, we examined the effect of apyrase (10 U/mL), which hydrolyses ATP to ADP, 
addition to the extracellular media on cardiomyocyte contraction rate.  Apyrase had no inhibitory 
effect on baseline contraction rate and did not prevent isoproteronol from significantly increasing 
cardiomyocyte contraction rate; however, this stimulated response was significantly less than 
control experiments (39 ± 3 vs. 62 ± 4 ∆beats/min, p < 0.01) (Figure A.4).  In addition to ATP, 
ADP, and AMP are also important extracellular signaling molecules.  Therefore, with these 
observations alone, we cannot rule out a role for extracellular ATP signaling in regulating 
cardiomyocyte contraction rate, nor the potential for CFTR to conduct ATP in cardiac myocytes.  
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However, we can conclude that our observed effects on cardiomyocyte contraction rate by CFTR 
inhibition are not primarily attributed to ATP conduction.  
 
EFFECT OF SWELLING-ACTIVATED Cl- CHANNEL INHIBITION ON 
CARDIOMYOCTE CONTRACTION RATE   
In understanding the role of CFTR as a Cl- channel in the heart we sought to determine if 
all outwardly conducting Cl- channels exhibit the same influence on cardiomyocyte contraction 
rate.  In addition to CFTR and Ca2+-activated Cl- channels, which we have shown to be involved 
in mediating contraction rate (Chapter 2), swelling-activated Cl- channels (otherwise known as 
stretch- or volume-activated Cl- channels) are also expressed in the heart.  Therefore, using 
tamoxifen, a specific inhibitor of swelling-activated Cl- channels at micromolar concentrations, 
we investigated the role of swelling-activated Cl- channels in contraction rate.  In contrast to 
CFTR and Ca2+-activated Cl- channels, inhibition of swelling-activated Cl- channels led to a 
time-dependent decrease in baseline contraction rate, which could not be overcome by addition 
of isoproterenol (Figure A.5).  These data show that: 1) swelling-activated Cl- channels are vital 
to maintaining proper contraction rate, and 2) not all outward conducting Cl- channels have the 
same role in regulating contraction rate. 
 
EFFECT OF 4,4,-DIISOTHIOCYANOSTILBENE SULFONIC ACID (DIDS) ON 
CARDIOMYOCYTE CONTRACTION RATE 
In numerous tissues evidence has shown that when CFTR and Cl-/HCO3- anion 
exchangers are expressed, they functionally interact to modulate HCO3- secretion and pHi.  To 
determine whether this phenomenon occurs in ventricular myocytes and can affect contraction 
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rate, we examined whether the anion exchanger inhibitor DIDS (1 mM) affects cardiomyocyte 
contraction rate in the presence and absence of CFTR inhibition.  We found that application of 
DIDS alone minimally affected basal contraction rate and fully prevented isoproteronol-
stimulated increases in contraction rate (Figure A.6A). The initial decrease in beating upon 
application of DIDS was due to biological actions of DIDS on cardiomyocytes, as addition of 
vehicle had no inhibitory effect on either baseline or isoproteronol-stimulated contraction rate.  
Inhibition of CFTR by CFTRinh-172 (20 µM) following DIDS resulted in a further decrease in 
contraction rate that remained unchanged upon isoproteronol stimulation (Figure A.6B).  When 
we examined the effect of DIDS in CFTR KO, we found that DIDS minimally inhibited baseline 
contraction rate, but fully prevented any increase in isoproteronol-stimulated contraction rate, 
similar to CFTRinh-172 (Figure A.6C).  From these studies we have found that while DIDS has a 
minimal effect of baseline contraction rate, however, it completely blocks isoproteronol-
stimulated contraction rate, regardless of CFTR activity. 
One caveat to be considered when interpreting these studies is that DIDS is a non-
selective inhibitor of anion exchange.  In addition to anion exchangers, DIDS has also been used 
to inhibit the Na:HCO3- contransporter (NBC), swelling-activated and Ca2+-activated Cl- 
channels.  As the inhibition of contraction rate produced by DIDS did not resemble that of 
tamoxifen (Figure A.5) or niflumic acid (Chapter 2, 4), which selectively inhibit swelling- or 
Ca2+-activated Cl- channels, respectively, we examined if the observed effect with DIDS could be 
due to inhibition of the NBC. To determine this we performed similar experiments with the 
selective NBC inhibitor, SO859. SO859 (10 µM) had no inhibitory effect on baseline or 
isoproteronol-stimulated increases in cardiomyoctye contraction rate (data not shown, n = 4, P > 
0.05), thereby indicating that inhibition of NBC by DIDS does not explain the effect of DIDS on 
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baseline or isoproteronol-stimulated contraction rate.  As a result, we conclude that the observed 
inhibitory effects of DIDS are due to inhibition of anion exchange.  As we have previously 
shown that HCO3- removal has no inhibitory effect on contraction rate (Figure A.3), we believe 
that this involves Cl-/OH-, not Cl-/HCO3-, exchange.  
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.1.  Effect of glibenclamide and DPC on cardiomyocyte contraction rate.  Similar to 
experiments in Chapter 2, neonatal cardiomyocytes were treated with DMSO (n = 7), 
glibenclamide (100 µM, n = 7), or DPC (500 µM, n = 7) for 20 minutes following a 10-minute 
baseline.  **, P < 0.01; ***, P < 0.001 glibenclamide vs. DMSO by two-way ANOVA.  +, P < 
0.05; +++, P < 0.001 DPC vs. DMSO by two-way ANOVA. 
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Figure A.2.  Role of hyperpolarization-activate ‘funny’ channels in cardiomyocyte 
contraction rate. Syncytial WT ventricular myocytes were treated with ZD7288 (0.1-100 µM, n 
= 3) for 30 minutes, following a 10-minute baseline.  Data are expressed as actual contraction 
rates (A) or peak inhibitory compared to baseline (B). 
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Figure A.3. Effect of HCO3- removal on cardiomyocyte contraction rate. Baseline (A) and 
isoproterenol-stimulated (B, 10 µM) contraction rates of WT syncytial cardiomyocytes were 
examined in the presence (control, n = 6) or absence of extracellular HCO3- (HCO3--free, n = 7), 
or total HCO3- removal (HCO3--free + 100 µM acetazolamide, n = 7).  Baseline data are 
expressed as actual values, whereas isoproterenol-stimulated data are expressed as peak 
responses subtracted from their respective baseline values.  Neither group was statistically 
significant (P > 0.05) from control data. 
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Figure A. 4.  Role of external ATP in cardiomyocyte contraction rate. Syncytial WT 
ventricular myocytes were treated with H2O (n = 5) or Apyrase (10 U/mL, n = 5) for 10 minutes 
prior to stimulation.  Subsequently, myocytes were stimulated with isoproterenol (10 µM) for an 
additional 30 minutes. 
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Figure A.5.  Effect of swelling-activated Cl- channel inhibition on cardiomyocyte 
contraction rate. Syncytial WT ventricular myocytes were treated with tamoxifen (10µM, n = 
5) or vehicle control (n = 3) for 50 minutes following a 10-minute baseline.  In additional 
experiments (n = 4) isoproterenol (10 µM) was added 20 minutes after tamoxifen for 30 minutes. 
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Figure A.6.  Effect of DIDS on cardiomyocyte contraction rate.  A and B.  Syncytial WT 
ventricular myocytes were treated with DIDS (1 mM, n = 6), vehicle control (0.1 M KHCO3, n = 
5), and/or CFTRinh-172 (20 µM, n = 5) for 20 minutes following a 10-minute baseline. C. 
Syncytial CFTR KO ventricular myocytes were treated with DIDS (1 mM, n = 6) for 20 minutes 
following a 10-minute baseline.  Subsequently, all cell were treated with isoproteronol (10 µM) 
for 30 minutes. 
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Figure A.6 continued… 
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a novel GC-C- and CFTR-independent pathway.  FASEB J. 2008 May;22(5):1306-16. 
10. Lin Z, K Witschas, T Garcia, RS Chen, JP Hansen, ZM Sellers, E Kuzmenkina, S Herzig, 
PM Best.  A critical GxxxA motif in the first transmembrane domain of the γ6 calcium 
channel subunit mediates its inhibitory effect on Cav3.1 calcium current. J Physiol. 2008 Nov 
15;586(Pt 22):5349-66. 
11. Sellers ZM, H Dong.  Response to: "Is an increase in duodenal bicarbonate concentration 
after STa really enhanced bicarbonate ion secretion?" FASEB J. 2009 Feb;23(2):295-6. 
 
OTHER PUBLICATIONS 
 
1. Els C, ZM Sellers.  “Gastrointestinal Physiology.” University of Illinois College of Medicine 
at Urbana-Champaign First Year Curriculum.  Board of Trustees of the University of Illinois: 
Urbana, 2008. 1-22. 
 
PUBLICATIONS IN PREPARATION/PROGRESS 
 
1. Sellers ZM, V De Arcangelis, Y Xiang, PM Best. Disruption of CFTR in cardiomyocytes 
requires CaMKII and Ca2+-activated Cl- channels to maintain contraction rate. Submitted to 
Journal of Physiology. 
2. Sellers ZM, AP Naren, Y Xiang, PM Best. Multi-drug resistant protein 4 in cardiac 
myocytes: another player in the regulation of intracellular cAMP and β-adrenergic signaling. 
In preparation for submission to AJP-Heart and Circulatory Physiology. 
3. Sellers ZM, D Soto, Y Xiang, PM Best.  In vitro and in vivo examination of CFTR in β-
adrenergic stimulated heart function. 
4. Sellers ZM, AJ Smith, M Soleimani, U Seidler, KE Barrett, H Dong. Central role for 
carbonic anhydrase and PAT-1 in STa-stimulated duodenal HCO3- secretion in CFTR 
knockout mice. 
5. Dong H, ZM Sellers, JY Chow, AJ Smith, KE Barrett.  Expression and function of TRP 
channel in duodenal mucosal regulation of Ca2+-dependent ion transport. 
6. Broderick A, LR Hagey, ZM Sellers, AF Hofmann, MC Carey. Nor-ursodeoxycholic but not 
ursodeoxycholic acid feeding normalizes biliary pH and reduces unconjugated bilirubin in 
bile in G551D cystic fibrosis mice. 
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7. Solicited article for The Physiologist (a publication of the American Physiological Society) 
examining the activities of Physiology Ph.D. graduates.  Scheduled for publication in 
Summer-Fall 2010. 
 
ABSTRACTS PRESENTED AT INTERNATIONAL CONFERENCES 
 
1. Crombie D, S Keely, DL Hogan, Z Sellers, K Barrett, J Isenberg, V Pratha.  PGE2-stimulated 
human duodenal epithelial bicarbonate secretion involves MAPK (ERK) activation.  
Gastroenterology 2001; 120 (5): A247.  Digestive Disease Week. 
2. Childs D, D Crombie, V Pratha, Z Sellers, DL Hogan, JI Isenberg.  Heat stable toxin of E. 
Coli (STa) stimulated duodenal mucosal bicarbonate secretion in cystic fibrosis knockout 
mice.  Gastroenterology 2001; 120 (5): A527. Digestive Disease Week. 
3. Tuo B, V Pratha, Z Sellers, SP Rao, JI Isenberg.  CagA+/VacA+ positivity of Helicobacter 
pylori mediates the inhibition of agonist-stimulated duodenal mucosal bicarbonate secretion 
(DMBS) in mice in vitro.  Gastroenterology 2002;122 (4): A227. Digestive Disease Week. 
4. Rao SP, Z Sellers, P Paulus, G Perez-Perez, M Blaser, JI Isenberg, V Pratha.  H. pylori alters 
bicarbonate secretion and signal transduction events in human duodenal mucosa in vitro: a 
CagA/VacA-dependent effect.  Gastroenterology 2002;122 (4): A515. Digestive Disease 
Week. 
5. Pompa D, Z Sellers, P Paulus, JI Isenberg, R Mittal, V Pratha.  Human esophageal 
epithelium in vitro: a novel technique using endoscopic biopsies.  Gastroenterology 2002;122 
(4): A112. Digestive Disease Week. 
6. Tuo B, P Paulus, Z Sellers, JI Isenberg.  5-hydroxytryptamine 4 receptors mediate 5-
hydroxytryptamine-induced duodenal mucosal bicarbonate secretion in mice.  
Gastroenterology 2003;124 (4): A452. Digestive Disease Week. 
7. Sellers Z, B Tuo, S Keely, JI Isenberg.  ERK-phosphorylation regulates basal, but not 
agonist-stimulated duodenal mucosal bicarbonate secretion in murine duodenum in vitro.  
Gastroenterology 2003;124 (4): A444. Digestive Disease Week. 
8. Sellers Z, P Kumar, J Steinbach, N Khalili, B Macias, D Watenpaugh, E. Groppo, AR 
Hargens, V Pratha.  Colonic motility is unaltered by lower body negative pressure exercise 
during prolonged antiorthostatic bedrest-implications for spaceflight.  Gastroenterology 
2003;124 (4): A572. Digestive Disease Week. 
9. Dohil R, R Newbury, Z Sellers, R Deutsch, J Schneider.  The evaluation of gastrointestinal 
disease and effect of Omeprazole therapy in children with cystinosis receiving cysteamine.  
Gastroenterology 2003;124 (4): A516. Digestive Disease Week. 
10. Dong H, ZM Sellers, JYC Chow, KE Barrett.  Intracellular Ca2+ handling mechanisms 
during duodenal mucosal ion transport in mice. Gastroenterology 2004;126 (4): A534. 
Digestive Disease Week. 
11. Sellers ZM, AJ Smith, H Dong, KE Barrett.  STa stimulates a novel bicarbonate secretory 
pathway in CFTR knockout mice.  Gastroenterology 2004;126 (4): A297. Digestive Disease 
Week. 
12. Dong H, ZM Sellers, A Smith, X Wang, KE Barrett.  Role of Na+/Ca2+ exchange in the 
regulation of duodenal mucosal bicarbonate secretion.  Experimental Biology and XXXV 
International Congress of Physiological Sciences, 2005. 
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13. Sellers ZM, H Dong, KE Barrett.  STa and uroguanylin stimulate distinct guanylyl cyclase 
C-independent duodenal bicarbonate secretory pathways in mice.  Gastroenterology 
2005;128 (4): A116. Digestive Disease Week. 
14. Sellers ZM, A Smith, H Dong, KE Barrett.  Differential roles of carbonic anhydrase and 
Na+/HCO3- cotransporter in STa-stimulated duodenal mucosal bicarbonate secretion in 
normal and cystic fibrosis mice.   Gastroenterology 2005;128 (4): A347. Digestive Disease 
Week. 
15. Dong H, A Smith, ZM Sellers, JYC Chow, KE Barrett.  Role of TRPV channels in the 
regulation of duodenal mucosal bicarbonate secretion. Gastroenterology 2005;128 (4): A365. 
Digestive Disease Week. 
16. Dohil R, M Fidler, R Newbury, Z Sellers, R Deutsch, J Schneider.  Esomeprazole Therapy 
for Gastric Acid Hypersecretion in Children Receiving Regular Cysteamine. 
Gastroenterology 2005;128 (4): A300. Digestive Disease Week. 
17. Sellers ZM, Y Xiang, PM Best.  CFTR is involved in the regulation of cardiomyocyte 
contraction rate.  Pediatric Pulmonology 2007; 30: 218.  North American Cystic Fibrosis 
Conference. 
18. Sellers ZM, Y Xiang, PM Best.  Regulation of basal and beta-adrenergic-stimulated 
ventricular cardiomyocyte contraction rate involves distinct populations of chloride channels.  
Experimental Biology 2008. 
19. Sellers ZM, Y Xiang, PM Best. Inhibition of the cystic fibrosis transmembrane conductance 
regulator in cardiomyocytes causes alterations in PKA activity and intracellular Ca2+.  The 
Beijing Joint Conference of Physiological Sciences 2008. 
20. Sellers ZM, Y Xiang, PM Best.  CFTR inhibition leads to stimulation of calcium-activated 
Cl- channels through alterations in intracellular Ca2+.  North American Cystic Fibrosis 
Conference 2008. 
21. Sellers ZM, AP. Naren, Yang Xiang, PM Best.  Functional Interaction of CFTR and MRP4 
in mediating β1-adrenergic receptor stimulated increases in cardiomyocyte contraction rate.  
Experimental Biology 2009. 
22. Sellers ZM, Y Xiang, PM Best. CFTR is responsible for modulating local β1-adrenergic 
receptor stimulated increases in cardiomyocyte contraction rate.  Experimental Biology 2009. 
 
INVITED PRESENTATIONS 
 
2005  West Coast Salt and Water Club, 24th Annual Meeting 
“Escherichia coli heat-stable enterotoxin (STa) and bicarbonate secretion:   
   implications for cystic fibrosis” 
 
2005  Digestive Disease Week  
“STa and uroguanylin stimulate distinct guanylyl cyclase C-independent  
   duodenal bicarbonate secretory pathways in mice” 
 
2008, 2009 Experimental Biology, Undergraduate Student Orientation 
“Tips for attending and presenting a poster” 
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2008  Department of Physiology, Cardiovascular Group  
University of Tennessee-Memphis      
“CFTR in the heart: redundant or important protein for cardiac function” 
 
2008 ICLCS: Institute for Chemistry Literacy Through Computational Science 
University of Illinois at Urbana-Champaign   
“Cystic fibrosis: applying lessons from the clinic and research to the  classroom” 
 
2009  Department of Molecular and Integrative Physiology, Department Seminar  
   University of Illinois at Urbana-Champaign     
“Understanding the role of CFTR in the heart: a look at cardiomyocyte   
   contraction rate” 
 
2009  College of Medicine, Clinical Research Conference Series  
University of Illinois at Urbana-Champaign    
“Cystic fibrosis and heart disease?” 
 
2009  Department of Molecular and Integrative Physiology, Retreat   
  University of Illinois at Urbana-Champaign     
“Phenotyping CFTR knockout mice to explore the cardiac health of CF patients” 
 
RESEARCH GRANT SUPPORT 
 
2006-2008 Author and Co-Investigator (P.I. Hui Dong, UCSD) 
Pilot and Feasibility Grant, Cystic Fibrosis Foundation 
 “Identification of a non-CFTR bicarbonate secretory pathway stimulated by STa” 
 
2006-2007 Author and primary researcher (P.I. Philip Best, UIUC) 
Research Board Grant, University of Illinois at Urbana-Champaign 
“A small peptide modulator of cardiac calcium current” 
 
2007  Principal Investigator 
College of Medicine, Hazel I. Craig Fellowship, University of Illinois at Urbana- 
   Champaign 
“Exploring functional interactions between CFTR and the hyperpolarization- 
   activated current in the heart” 
 
2008-2010 Principal Investigator 
Pre-doctoral Fellowship, American Heart Association 
“Role of CFTR in modulation of cardiomyocyte contraction rate” 
 
COMMITTEE SERVICE 
 
2006, 2007 Annual Research Symposium Committee 
Department of Molecular and Integrative Physiology 
University of Illinois at Urbana-Champaign 
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2008-2010 Career Opportunities in Physiology Committee 
American Physiological Society      
 
2007-present Founder and Coordinator 
Cystic Fibrosis Focus Group 
  University of Illinois at Urbana-Champaign 
 
2008-present Ad hoc consultant on cystic fibrosis 
ICLCS: Institute for Chemistry Literacy Through Computational Science One   
   Gene Chemistry Educational Module     
University of Illinois at Urbana-Champaign 
 
PROFESSIONAL ASSOCIATIONS 
 
2005-2009 Sigma Xi Research Society       
 
2006-2009 Collegium Aesculapium      
 
2007-2008 American Gastroenterological Association   
 
2007-2008 American Association for the Advancement of Science 
 
2005-present American Physiological Society      
 
2007-present American Academy of Pediatrics   
 
2008-present American Medical Student Association    
 
TEACHING 
 
2004  Guest Lecturer  
Visualizing the Microworld, University of California, San Diego   
“Helicobacter pylori”   
 
2006  Guest Lecturer 
MCB404 Systems and Integrative Physiology, Molecular and Cellular Biology,   
   University of Illinois at Urbana-Champaign    
“Epithelial Transport” 
 
2006-2007 Assistant Surgeon 
Cardiovascular Pig Lab, Molecular and Cellular Biology, University of Illinois at  
   Urbana-Champaign  
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2007 Teaching Assistant 
MCB404 Systems and Integrative Physiology, Molecular and Cellular Biology,  
   University of Illinois at Urbana-Champaign 
 
2007-2008 Teaching Assistant 
Medical Physiology, College of Medicine, University of Illinois at  Urbana- 
   Champaign 
 
2008-2010 Head Surgeon    
Cardiovascular Pig Lab, Molecular and Cellular Biology, University of Illinois at  
   Urbana-Champaign 
 
COMMUNITY SERVICE RELATED TO PROFESSIONAL WORK 
 
2002-2005 Surgical Day Coordinator 
Fresh Start Surgical Gifts, San Diego, CA 
 
2003-2005 Volunteer 
Free Health Clinic, University of California, San Diego 
 
2005  Participant 
Cystic Fibrosis Great Strides Walk, Urbana, Illinois 
 
2008 Presentations to 5-12 year olds on cystic fibrosis 
Society of Women Engineers Take Your Sons/Daughters to Work Day 
 
2009-present Hermes Free Health Clinic 
  UIUC College of Medicine, Urbana, IL 
 
 
 
